U.S. patent application number 11/686023 was filed with the patent office on 2007-07-12 for 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives.
Invention is credited to Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Peter Traxler.
Application Number | 20070161632 11/686023 |
Document ID | / |
Family ID | 9919959 |
Filed Date | 2007-07-12 |
United States Patent
Application |
20070161632 |
Kind Code |
A1 |
Bold; Guido ; et
al. |
July 12, 2007 |
4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
Abstract
The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives
of formula I ##STR1## wherein the symbols and substituents are as
defined in the description, to processes for the preparation
thereof, to pharmaceutical compositions comprising such derivatives
and to the use of such derivatives--alone or in combination with
one or more other pharmaceutically active compounds--for the
preparation of pharmaceutical compositions for the treatment
especially of a proliferative disease, such as a tumour.
Inventors: |
Bold; Guido;
(Gipf-Oberfrick, CH) ; Capraro; Hans-Georg;
(Rheinfelden, CH) ; Caravatti; Giorgio;
(Bottmingen, CH) ; Traxler; Peter; (Schoenenbuch,
CH) |
Correspondence
Address: |
NOVARTIS;CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER
NJ
07936-1080
US
|
Family ID: |
9919959 |
Appl. No.: |
11/686023 |
Filed: |
March 14, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10485747 |
Feb 3, 2004 |
|
|
|
PCT/EP02/08780 |
Aug 6, 2002 |
|
|
|
11686023 |
Mar 14, 2007 |
|
|
|
Current U.S.
Class: |
514/234.5 ;
514/252.16; 514/265.1; 544/114; 544/280 |
Current CPC
Class: |
C07D 487/04 20130101;
A61P 43/00 20180101; A61P 35/00 20180101 |
Class at
Publication: |
514/234.5 ;
514/265.1; 514/252.16; 544/114; 544/280 |
International
Class: |
A61K 31/5377 20060101
A61K031/5377; A61K 31/519 20060101 A61K031/519; C07D 487/04
20060101 C07D487/04 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 7, 2001 |
GB |
0119249.1 |
Claims
1-15. (canceled)
16. A compound selected from the group consisting of
(3-chloro-4-fluoro-phenyl)-(6-{4-[(tetrahydro-pyran-4-ylamino)-methyl]-ph-
enyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
(3-chloro-4-fluoro-phenyl)-(6-{4-[(2-morpholin-4-yl-ethylamino)-methyl]-p-
henyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
N-{4-[4-(3-chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]--
benzyl}-N',N'-diethyl-ethane-1,2-diamine;
(3-chloro-4-fluoro-phenyl)-{6-[4-(isopropylamino-methyl)-phenyl]-7H-pyrro-
lo[2,3-d]pyrimidin-4-yl}-amine;
(6-{4-[(2-morpholin-4-yl-ethylamino)-methyl]-phenyl}-7H-pyrrolo[2,3-d]pyr-
imidin-4-yl)-((R)-1-phenyl-ethyl)-amine;
((R)-1-phenyl-ethyl)-(6-{4-[(tetrahydro-pyran-4-ylamino)-methyl]-phenyl}--
7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
N,N-diethyl-N'-{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-
-6-yl]-benzyl}-ethane-1,2-diamine;
{6-[4-(tert-butylamino-methyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-(-
(R)-1-phenyl-ethyl)-amine;
{6-[4-(isopropylamino-methyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-((-
R)-1-phenyl-ethyl)-amine;
[6-(4-ethylaminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-ph-
enyl-ethyl)-amine;
[6-(4-methylaminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-p-
henyl-ethyl)-amine;
(3-methoxy-benzyl)-[6-(4-morpholin-4-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-amine;
(3-methoxy-benzyl)-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrro-
lo[2,3-d]pyrimidin-4-yl}-amine;
{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-
-yl}-(3-methoxy-benzyl)-amine;
(3-methyl-benzyl)-[6-(4-piperidin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyr-
imidin-4-yl]-amine;
(3-methyl-benzyl)-[6-(4-morpholin-4-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyr-
imidin-4-yl]-amine;
[6-(4-dimethylaminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-(3-met-
hyl-benzyl)-amine;
[6-(4-diethylaminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-(3-meth-
yl-benzyl)-amine;
(3-methyl-benzyl)-[6-(4-pyrrolidin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-amine;
(3-methyl-benzyl)-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrol-
o[2,3-d]pyrimidin-4-yl}-amine;
{-6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin--
4-yl}-(3-methyl-benzyl)-amine;
benzo[1,3]dioxol-5-yl-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyr-
rolo[2,3-d]pyrimidin-4-yl}-amine;
(6-methoxy-pyridin-3-yl)-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H--
pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
5-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-
-4-ylamino}-1H-pyridin-2-one;
(6-methoxy-pyridin-3-ylmethyl)-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-pheny-
l]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
(6-methoxy-pyridin-3-ylmethyl)-{6-[4-(morpholin-4-ylmethyl)-phenyl]-7H-py-
rrolo[2,3-d]pyrimidin-4-yl}-amine;
(6-methoxy-pyridin-3-ylmethyl)-{6-[4-(dimethylamino-methyl)-phenyl]-7H-py-
rrolo[2,3-d]pyrimidin-4-yl}-amine;
(2-methoxy-pyridin-4-ylmethyl)-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-pheny-
]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
(2-methoxy-pyridin-4-ylmethyl)-{6-[4-(morpholin-4-ylmethyl)-phenyl]-7H-py-
rrolo[2,3-d]pyrimidin-4-yl}-amine;
(2-methoxy-pyridin-4-ylmethyl)-{6-[4-(dimethylamino-methyl)-phenyl]-7H-py-
rrolo[2,3-d]pyrimidin-4-yl}-amine;
(2-methoxy-pyridin-4-ylmethyl)-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-pheny-
l]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
5-({6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidi-
n-4-ylamino}-methyl)-1H-pyridin-2-one;
5-({6-[(4-(dimethylamino-methyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yla-
mino}-methyl)-1H-pyridin-2-one;
5-({6-[4-(4-morpholin-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylam-
ino}-methyl)-1H-pyridin-2-one;
4-({6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidi-
n-4-ylamino}-methyl)-1H-pyridin-2-one;
4-({6-[4-(4-morpholin-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylam-
ino}-methyl)-1H-pyridin-2-one;
4-({6-[(4-(dimethylamino-methyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yla-
mino}-methyl)-1H-pyridin-2-one;
4-({6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimid-
in-4-ylamino}-methyl)-1H-pyridin-2-one;
(2-methoxy-pyridin-4-yl)-[6-(4-morpholin-4-ylmethyl-phenyl)-7H-pyrrolo[2,-
3-d]pyrimidin-4-yl]-amine;
(2-methoxy-pyridin-4-yl)-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-
-pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
(2-methoxy-pyridin-4-yl)-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H--
pyrrolo[2,3-d]pyrimidin-4-yl}-amine;
4-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-
-4-ylamino}-1H-pyridin-2-one; and pharmaceutically acceptable salts
thereof.
17. A compound selected from the group consisting of
(4-methyl-piperazin-1-yl)-{4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-p-
yrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanone;
{4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-y-
l]-phenyl}-morpholin-4-yl-methanone;
4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-N,N-dimethyl-benzamide; and pharmaceutically acceptable salts
thereof.
18. A compound selected from the group consisting of
6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-4-(4-fluoro-2-methyl-1H-indol-
-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidine;
6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-4-(4-fluoro-2-methyl-1H-indo-
l-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidine;
4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-(4-morpholin-4-ylmethyl-phenyl)--
7H-pyrrolo[2,3-d]pyrimidine;
{4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-y-
l]-benzyl}-dimethyl-amine; and pharmaceutically acceptable salts
thereof.
Description
[0001] The invention relates to 7H-pyrrolo[2,3-d]pyrimidine
derivatives and to processes for the preparation thereof, to
pharmaceutical compositions comprising such derivatives and to the
use of such derivatives--alone or in combination with one or more
other pharmaceutically active compounds--for the preparation of
pharmaceutical compositions for the treatment especially of a
proliferative disease, such as a tumour.
[0002] The invention relates to 7H-pyrrolo[2,3-d]pyrimidine
derivatives of formula I ##STR2## wherein [0003] R.sub.1 and
R.sub.2 are each independently of the other hydrogen, unsubstituted
or substituted alkyl or cycloalkyl, a heterocyclic radical bonded
via a ring carbon atom, or a radical of the formula
R.sub.4--Y--(C.dbd.Z)-- wherein R.sub.4 is unsubstituted, mono- or
disubstituted amino or a heterocyclic radical, Y is either not
present or lower alkyl and Z is oxygen, sulfur or imino, with the
proviso that R.sub.1 and R.sub.2 are not both hydrogen; or [0004]
R.sub.1 and R.sub.2 together with the nitrogen atom to which they
are attached form a heterocyclic radical; [0005] R.sub.3 is a
heterocyclic radical or an unsubstituted or substituted aromatic
radical; [0006] G is C.sub.1-C.sub.7-alkylene, C(.dbd.O)--, or
C.sub.1-C.sub.6-alkylene-C(.dbd.O)-- wherein the carbonyl group is
attached to the NR.sub.1R.sub.2 moiety; [0007] Q is --NH-- or
--O--, with the proviso that Q is --O-- if G is --C(.dbd.O)-- or
C.sub.1-C.sub.6-alkylene-C(.dbd.O)--; and [0008] X is either not
present or C.sub.1-C.sub.7-alkylene, with the proviso that a
heterocyclic radical R.sub.3 is bonded via a ring carbon atom if X
is not present; or a salt of the said compounds.
[0009] The general terms used hereinbefore and hereinafter
preferably have within the context of this disclosure the following
meanings, unless otherwise indicated:
[0010] Where the plural form is used for compounds, salts, and the
like, this is taken to mean also a single compound, salt, or the
like.
[0011] Where compounds of formula I are mentioned which can form
tautomers, it is meant to include also the tautomers of such
compounds of formula I. In particular, tautomerism occurs e.g. for
compounds of formula I which contain a 2-hydroxy-pyridyl radical
(see e.g. radical R.sub.3 of the below-mentioned Examples 115-120).
In such compounds the 2-hydroxy-pyridyl radical can also be present
as pyrid-2(1H)-on-yl.
[0012] Asymmetric carbon atoms of a compound of formula I that are
optionally present may exist in the (R), (S) or (R,S)
configuration, preferably in the (R) or (S) configuration.
Substituents at a double bond or a ring may be present in cis-(=Z-)
or trans (=E-) form. The compounds may thus be present as mixtures
of isomers or preferably as pure isomers.
[0013] Preferably alkyl contains up to 20 carbon atoms and is most
preferably lower alkyl.
[0014] The prefix "lower" denotes a radical having up to and
including a maximum of 7, especially up to and including a maximum
of 4 carbon atoms, the radicals in question being either unbranched
or branched with single or multiple branching.
[0015] Lower alkyl is, for example, methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
isopentyl, neopentyl, n-hexyl or n-heptyl.
[0016] Alkyl R.sub.1 and R.sub.2 independently of each other are
preferably methyl, ethyl, isopropyl or tert-butyl, especially
methyl or ethyl.
[0017] Lower alkyl Y is preferably methyl, ethyl or propyl.
[0018] Lower alkoxy is for example ethoxy or methoxy, especially
methoxy.
[0019] Substituted alkyl is preferably lower alkyl as defined above
where one or more, preferably one, substituents may be present,
such as e.g. amino, N-lower alkylamino, N,N-di-lower alkylamino,
N-lower alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower
alkoxy, lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy,
lower alkoxycarbonyl, carbamoyl, N-lower alkyl-carbamoyl,
N,N-di-lower alkyl carbamoyl, amidino, guanidino, ureido, mercapto,
lower alkylthio, halogen or a heterocyclic radical.
[0020] Substituted alkyl R.sub.1 and R.sub.2 are independently of
each other preferably hydroxy-lower alkyl, N,N-di-lower
alkylamino-lower alkyl or morpholinyl-lower alkyl.
[0021] Preferably unsubstituted or substituted cycloalkyl R.sub.1
or R.sub.2 contains from 3 up to 20 carbon atoms and is especially
unsubstituted or also substituted C.sub.3-C.sub.5 cycloalkyl
wherein the substituents are selected from e.g. unsubstituted or
substituted lower alkyl, amino, N-lower alkylamino, N,N-di-lower
alkylamino, N-lower alkanoylamino, N,N-di-lower alkanoylamino,
hydroxy, lower alkoxy, lower alkanoyl, lower alkanoyloxy, cyano,
nitro, carboxy, lower alkoxycarbonyl, carbamoyl, N-lower
alkyl-carbamoyl, N,N-di-lower alkyl-carbamoyl, amidino, guanidino,
ureido, mercapto, lower alkylthio, halogen or a heterocyclic
radical.
[0022] Mono- or disubstituted amino is amino substituted by one or
two radicals selected independently of one another from e.g.
unsubstituted or substituted lower alkyl.
[0023] Disubstituted amino R.sub.4 is preferably N,N-di-lower
alkylamino, especially N,N-dimethylamino or N,N-diethylamino.
[0024] A heterocyclic radical contains especially up to 20 carbon
atoms and is preferably a saturated or unsaturated monocyclic
radical having from 4 or 8 ring members and from 1 to 3 heteroatoms
which are preferably selected from nitrogen, oxygen and sulfur, or
a bi- or tri-cyclic radical wherein, for example, one or two
carbocyclic radicals, such as e.g. benzene radicals, are annellated
(fused) to the mentioned monocyclic radical. If a heterocyclic
radical contains a fused carbocydic radical then the heterocyclic
radical may also be attached to the rest of the molecule of formula
I via a ring atom of the fused carbocydic radical. The heterocyclic
radical (including the fused carbocyclic radical(s) if present) is
optionally substituted by one or more, preferably by one or two,
radicals such as e.g. unsubstituted or substituted lower alkyl,
amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower
alkanoylamino, N,N-di-lower alkanoylamino, hydroxy, lower alkoxy,
lower alkanoyl, lower alkanoyloxy, cyano, nitro, carboxy, lower
alkoxycarbonyl, carbamoyl, N-lower alkyl-carbamoyl, N,N-di-lower
alkyl-carbamoyl, amidino, guanidino, ureido, mercapto, lower
alkylthio, or halogen.
[0025] Most preferably a heterocyclic radical is pyrrolidinyl,
piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl,
morpholinyl, tetrahydropyranyl, pyridyl, pyridyl substituted by
hydroxy or lower alkoxy, or benzodioxolyl, especially pyrrolidinyl,
piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl or
morpholinyl.
[0026] A heterocyclic radical R.sub.1 or R.sub.2 is as defined
above for a heterocyclic radical with the proviso that it is bonded
to the rest of the molecule of formula I via a ring carbon atom.
Preferably a heterocyclic radical R.sub.1 or R.sub.2 is lower
alkyl-piperazinyl or especially preferred tetrahydropyranyl. If one
of the two radicals R.sub.1 and R.sub.2 represents a heterocyclic
radical, the other is preferably hydrogen.
[0027] A heterocyclic radical R.sub.3 is as defined above for a
heterocyclic radical with the proviso that it is bonded to Q via a
ring carbon atom if X is not present. Preferably a heterocyclic
radical R.sub.3 is benzodioxolyl, pyridyl substituted by hydroxy or
lower alkoxy, or especially preferred indolyl substituted by
halogen and lower alkyl. If R.sub.3 is pyridyl substituted by
hydroxy then the hydroxy group is preferably attached to a ring
carbon atom adjacent to the ring nitrogen atom.
[0028] A heterocydic radical R.sub.4 is as defined above for a
heterocyclic radical and is preferably pyrrolidinyl, piperidyl,
lower alkyl-piperazinyl, morpholinyl or pyridyl.
[0029] If R.sub.1 and R.sub.2 together with the nitrogen atom to
which they are attached form a heterocyclic radical, the
heterocyclic radical is as defined above for a heterocyclic radical
and represents preferably pyrrolidinyl, piperidyl, lower
alkyl-piperazinyl, di-lower alkyl-piperazinyl or morpholinyl.
[0030] An unsubstituted or substituted aromatic radical R.sub.3 has
up to 20 carbon atoms and is unsubstituted or substituted, for
example in each case unsubstituted or substituted phenyl.
[0031] Preferably an unsubstituted aromatic radical R.sub.3 is
phenyl. A substituted aromatic radical R.sub.3 is preferably phenyl
substituted by one or more substituents selected independently of
one another from the group consisting of unsubstituted or
substituted lower alkyl, amino, N-lower alkylamino, N,N-di-lower
alkylamino, N-lower alkanoylamino, N,N-di-lower alkanoylamino,
hydroxy, lower alkoxy, lower alkanoyl, lower alkanoyloxy, cyano,
nitro, carboxy, lower alkoxycarbonyl, carbamoyl, N-lower
alkyl-carbamoyl, N,N-di-lower alkyl-carbamoyl, amidino, guanidino,
ureido, mercapto, lower alkylthio and halogen. Most preferably a
substituted aromatic radical R.sub.3 is phenyl substituted by one
or more radicals selected independently of one another from the
group consisting of lower alkyl, amino, hydroxy, lower alkoxy,
halogen and benzyloxy.
[0032] Halogen is primarily fluoro, chloro, bromo or iodo,
especially fluoro, chloro or bromo.
[0033] C.sub.1-C.sub.7-alkylene may be branched or unbranched and
is in particular C.sub.1-C.sub.3-alkylene.
[0034] C.sub.1-C.sub.7-alkylene G is preferably
C.sub.1-C.sub.3-alkylene, most preferably methylene
(--CH.sub.2--).
[0035] If G is not C.sub.1-C.sub.7-alkylene it preferably
represents --C(.dbd.O)--.
[0036] C.sub.1-C.sub.7-alkylene X is preferably
C.sub.1-C.sub.3-alkylene, most preferably methylene (--CH.sub.2--)
or ethan-1,1-diyl (--CH(CH.sub.3)--).
[0037] Q is preferably --NH--.
[0038] Z is preferably oxygen or sulfur, most preferably
oxygen.
[0039] Salts are especially the pharmaceutically acceptable salts
of compounds of formula I.
[0040] Such salts are formed, for example, as acid addition salts,
preferably with organic or inorganic acids, from compounds of
formula I with a basic nitrogen atom, especially the
pharmaceutically acceptable salts.
[0041] In the presence of negatively charged radicals, such as
carboxy or sulfo, salts may also be formed with bases, e.g. metal
or ammonium salts, such as alkali metal or alkaline earth metal
salts, or ammonium salts with ammonia or suitable organic amines,
such as tertiary monoamines.
[0042] In the presence of a basic group and an acid group in the
same molecule, a compound of formula I may also form internal
salts.
[0043] For isolation or purification purposes it is also possible
to use pharmaceutically unacceptable salts, for example picrates or
perchlorates. Only the pharmaceutically acceptable salts or free
compounds (if the occasion arises, in the form of pharmaceutical
compositions) attain therapeutic use, and these are therefore
preferred.
[0044] In view of the close relationship between the novel
compounds in free form and in the form of their salts, including
those salts that can be used as intermediates, for example in the
purification or identification of the novel compounds, hereinbefore
and hereinafter any reference to the free compounds is to be
understood as referring also to the corresponding salts, as
appropriate and expedient.
[0045] The compounds of formula I have valuable, pharmacologically
useful properties. In particular they exhibit specific inhibitory
activities that are of pharmacological interest. They are effective
especially as protein tyrosine kinase inhibitors and/or
(furthermore) as inhibitors of serine/threonine protein kinases;
they exhibit, for example, powerful inhibition of the tyrosine
kinase activity of the epidermal growth factor receptor (EGF-R) and
of ErbB-2 kinase. These two protein tyrosine kinase receptors,
together with their family members ErbB-3 and ErbB-4, play a key
role in signal transmission in a large number of mammalian cells,
including human cells, especially epithelial cells, cells of the
immune system and cells of the central and peripheral nervous
system. For example, in various cell types, EGF-induced activation
of receptor-associated protein tyrosine kinase is a prerequisite
for cell division and hence for the proliferation of the cell
population. Most importantly, overexpression of the EGF-R (HER-1)
and/or ErbB-2 (HER-2) has been observed in substantial fractions of
many human tumours. EGF-R, e.g., was found to be overexpressed in
non small-cell lung cancers, squameous carcinoma (head and neck),
breast, gastric, ovarian, colon and prostate cancers as well as in
gliomas. ErbB-2 was found to be overexpressed in squameous
carcinoma (head and neck), breast, gastric, and ovarian cancers as
well as in gliomas.
[0046] In addition to inhibiting the tyrosine kinase activity of
the EGF-R, the compounds of formula I also inhibit to varying
extents other protein tyrosine kinases that are involved in signal
transmission mediated by trophic factors, specially the vascular
endothelial growth factor (VEGF) receptor family (e.g. KDR, Flt-1,
Flt-3) but also abl kinase, especially v-abl, kinases from the
family of Src, especially c-Src, Lck and Fyn, the other members of
the EGF receptor family such as ErbB-3 (HER-3) and ErbB-4 (HER-4),
CSF-1, Kit, FGF receptor and the cyclin-dependent kinases CDK1 and
CDK2, all of which play a part in growth regulation and
transformation in mammalian cells, including human cells.
[0047] The inhibition of EGF-R tyrosine kinase activity can be
demonstrated using known methods, for example using the recombinant
intracellular domain of the EGF-receptor [EGF-R ICD; see, for
example, E. McGlynn et al., Europ. J. Biochem. 207, 265-275
(1992)]. Compared with the control without inhibitor, the compounds
of formula I inhibit the enzyme activity by 50% (IC.sub.50), for
example in a concentration of from 0.0005 to 0.5 .mu.M, especially
from 0.001 to 0.1 .mu.M.
[0048] As well as or instead of inhibiting EGF-R tyrosine kinase
activity, the compounds of formula I also inhibit other members of
this family of receptors, like ErbB-2. The inhibitory activity
(IC.sub.50) is approximately in the range of 0.001 to 0.5 .mu.M.
The inhibition of ErbB-2 tyrosine kinase (HER-2) can be determined,
for example, analogously to the method used for EGF-R protein
tyrosine kinase [see C. House et al., Europ. J. Biochem. 140,
363-367 (1984)]. The ErbB-2 kinase can be isolated, and its
activity determined, by means of protocols known per se, for
example in accordance with T. Akiyama et al., Science 232, 1644
(1986).
[0049] Surprisingly, the compounds of formula I especially also
inhibit the tyrosine kinase activity of the VEGF receptor family
very potently. The compounds of the present invention are therefore
very effective dual inhibitors of EGF- and VEGF-receptor family
members. For inhibition of KDR and Flt-1 and inhibition of growth
factor-induced proliferation of HUVECS see J. Wood et al., Cancer
Res. 60, 2178-2189 (2000). The compounds of formula I inhibit e.g.
the KDR tyrosine kinase activity with an IC.sub.50 of from about 1
nM to about 1 .mu.M, especially from about 5 nM to about 0.5
.mu.M.
[0050] The action of the compounds of formula I on EGF-induced
phosphorylation of the EGF-R can be determined in the human A431
epithelial carcinoma cell line by means of an ELISA which is
described in U. Trnks et al., J. Med. Chem. 37:7, 1015-1027 (1994).
In that test (EGF-R ELISA) the compounds of formula I exhibit an
IC.sub.50 of approximately from 0.001 to 1 .mu.M.
[0051] The compounds of formula I potently inhibit the growth of
EGF-R overexpressing NCI-H596 non-small cell lung carcinoma cells
[see e.g. W. Lei, et al., Anticancer Res. 19(1A), 221-228 (1999)]
at an IC.sub.50 of approximately 0.01 to 1 .mu.M. In the same range
of activity, the compounds of formula I also potently inhibit the
growth of ErbB2-overexpressing BT474 human breast cancer cells. The
test procedures are adapted from T. Meyer et al., Int. J. Cancer
43, 851 (1989). The inhibitory activity of the compounds of formula
I is determined, briefly, as follows: NCI-H596 cells (10
000/microtitre plate well) are transferred to 96-well microtitre
plates. The test compounds [dissolved in dimethyl sulfoxide (DMSO)]
are added in a series of concentrations (dilution series) in such a
manner that the final concentration of DMSO is not greater than 1%
(v/v). After the addition, the plates are incubated for three days
during which the control cultures without test compound are able to
undergo at least three cell-division cycles. The growth of the
NCI-H596 cells is measured by means of methylene blue staining:
after the incubation the cells are fixed with glutaraldehyde,
washed with water and stained with 0.05% methylene blue. After a
washing step the stain is eluted with 3% HCl and the optical
density (OD) per well of the microtitre plate is measured using a
Titertek Multiskan (Titertek, Huntsville, Ala., USA) at 665 nm.
IC.sub.50 values are determined by a computer-aided system using
the formula:
IC.sub.50=[(OD.sub.test-OD.sub.start)/(OD.sub.control-OD.sub.start)].time-
s.100.
[0052] The IC.sub.50 value in those experiments is given as that
concentration of the test compound in question that results in a
cell count that is 50% lower than that obtained using the control
without inhibitor. The compounds of formula I exhibit inhibitory
activity with an IC50 in the range from approximately 0.01 to 1
.mu.M.
[0053] The compounds of formula I exhibit inhibition of the growth
of tumour cells also in vivo, as shown, for example, by the test
described below: the test is based on inhibition of the growth of
the human squamous lung carcinoma cell line NCI-H596 [ATCC HTB 178;
American Type Culture Collection, Rockville, Md., USA; see Santon,
J. B., et al., Cancer Research 46, 4701-4705 (1986) and Ozawa, S.,
et al., Int. J. Cancer 40, 706-710 (1987)], which is transplanted
into female BALB/c nude mice (Bomholtgard, Denmark). That carcinoma
exhibits a growth that correlates with the extent of the expression
of the EGF-R. Tumours are established after subcutaneous (s.c.)
injection of cells [a minimum of 2.times.10.sup.6 cells in 100
.mu.l phosphate-buffered saline (PBS) or medium] in carrier mice
(4-8 mice). Injections are made s.c. in the left flank of the mouse
mid-way between the tail and the head. The resulting tumours are
serially passaged for a minimum of three consecutive
transplantations prior to start of the treatment. During this time
tumour growth rates stabilize. Tumours are not passaged more than
12 times. For the therapy experiment tumour fragments of roughly 25
mg are transplanted s.c. into the left flank of the animals using a
13-gauge trocar needle under Forene.RTM. (Abbott, Schwitzerland)
anesthesia. Tumour growth and body weights are monitored twice per
week. All treatments are initiated when the tumour attains a volume
of 100 to 250 mm.sup.3. The tumour volumes are calculated using the
known formula Length.times.Diameter.sup.2.times..pi./6 [see Evans,
B. D., et al., Brit. J. Cancer 45, 466-8 (1982)]. Antitumour
activity is expressed as T/C % (mean increase of tumour volumes of
treated animals divided by the mean increase of tumour volumes of
control animals multiplied by 100%). At a dose of from 3 to 100
mg/kg of active ingredient, distinct inhibition of the tumour
growth is found, for example T/C % values of less than 50.
[0054] The compounds of formula I may inhibit other protein
tyrosine kinases that are involved in signal transmission mediated
by trophic factors, for example abl kinase, such as especially
v-abl kinase (IC.sub.50 for example from 0.01 to 5 .mu.M), kinases
from the family of the src kinases, such as especially c-src kinase
(IC.sub.50 for example from 0.1 to 10 .mu.M) and serine/threonine
kinases, for example protein kinase C, all of which are involved in
growth regulation and transformation in mammalian cells, including
human cells.
[0055] The above-mentioned inhibition of v-abl tyrosine kinase is
determined by the methods of N. Lydon et al., Oncogene Research 5,
161-173 (1990) and J. F. Geissler et al., Cancer Research 52,
44924498 (1992). In those methods [Val.sup.5]-angiotensin II and
[.gamma.-.sup.32P]-ATP are used as substrates.
[0056] The compounds of formula I which inhibit the tyrosine kinase
activity of the EGF-R or of the other protein tyrosine kinases
mentioned are therefore useful, for example, in the treatment of
benign or malignant tumours. The compounds of formula I are e.g.
able to simultaneously inhibit the growth of tumors with
deregulated EGF-R and/or ErbB-2 activity as well as to inhibit the
vascularisation of solid tumors triggered by VEGF. This combined
activity leads to an improved antitumour effect. (see also WO
02/41882). Moreover, the use of a dual inhibitor reduces the risk
of drug-drug interactions and further reduces the total drug load
as compared to a combination therapy. The compounds of formula I
are capable of slowing down tumor growth or effecting tumour
regression and of preventing the formation of tumour metastases and
the growth of micrometastases. They can be used especially in the
case of epidermal hyperproliferation (psoriasis), in the treatment
of neoplasias of epithelial character, e.g. mammary carcinomas, and
in leukaemias. In addition, the compounds of formula I can be used
in the treatment of those disorders of the immune system in which
several or, especially, individual protein tyrosine kinases and/or
(furthermore) serine/threonine protein kinases are involved; the
compounds of formula I can also be used in the treatment of those
disorders of the central or peripheral nervous system in which
signal transmission by several or, especially, a single protein
tyrosine kinase(s) and/or (furthermore) serine/threonine protein
kinase(s) is/are involved.
[0057] In general, the present invention relates also to the use of
the compounds of formula I for the inhibition of the mentioned
protein kinases, in particular to their use for the dual inhibition
of EGF- and VEGF-receptor family members.
[0058] The compounds according to the invention can be used both
alone and in combination with other pharmacologically active
compounds, for example together with inhibitors of the enzymes of
polyamine synthesis, inhibitors of protein kinase C, inhibitors of
other tyrosine kinases, cytokines, negative growth regulators, for
example TGF-.beta. or IFN-.beta., aromatase inhibitors,
antioestrogens and/or cytostatic drugs.
[0059] With the groups of preferred compounds of formula I
mentioned hereinafter, definitions of substituents from the general
definitions mentioned hereinbefore may reasonably be used, for
example, to replace more general definitions with more specific
definitions or especially with definitions characterized as being
preferred.
[0060] Preference is given to a compound of formula I, wherein
[0061] R.sub.1 and R.sub.2 are each independently of the other
hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a
heterocyclic radical bonded via a ring carbon atom, or a radical of
the formula R.sub.4--Y--(C.dbd.Z)-- wherein R.sub.4 is
unsubstituted, mono- or disubstituted amino or a heterocyclic
radical, Y is either not present or lower alkyl and Z is oxygen or
sulfur or imino, with the proviso that R.sub.1 and R.sub.2 are not
both hydrogen; or [0062] R.sub.1 and R.sub.2 together with the
nitrogen atom to which they are attached form a heterocyclic
radical; [0063] R.sub.3 is a heterocyclic radical or an
unsubstituted or substituted aromatic radical; [0064] G is
C.sub.1-C.sub.7-alkylene; [0065] Q is --NH-- or --O--; and [0066] X
is either not present or C.sub.1-C.sub.7-alkylene, with the proviso
that a heterocyclic radical R.sub.3 is bonded via a ring carbon
atom if X is not present; or a salt thereof.
[0067] Preference is further given to a compound of formula I,
wherein [0068] R.sub.1 and R.sub.2 are each independently of the
other hydrogen, unsubstituted or substituted alkyl or cycloalkyl, a
heterocyclic radical bonded via a ring carbon atom, or a radical of
the formula R.sub.4--Y--(C.dbd.Z)-- wherein R.sub.4 is
unsubstituted, mono- or disubstituted amino or a heterocyclic
radical, Y is either not present or lower alkyl and Z is oxygen,
sulfur or imino, with the proviso that R.sub.1 and R.sub.2 are not
both hydrogen; or [0069] R.sub.1 and R.sub.2 together with the
nitrogen atom to which they are attached form a heterocyclic
radical; [0070] R.sub.3 is a heterocyclic radical or an
unsubstituted or substituted aromatic radical; [0071] G is
C.sub.1-C.sub.7-alkylene; [0072] Q is --NH--; and [0073] X is
either not present or C.sub.1-C.sub.7-alkylene, with the proviso
that a heterocyclic radical R.sub.3 is bonded via a ring carbon
atom if X is not present; or a salt thereof.
[0074] Special preference is given to a compound of formula I,
wherein [0075] R.sub.1 and R.sub.2 are each independently of the
other hydrogen, unsubstituted or substituted lower alkyl or
C.sub.3-C.sub.6 cycloalkyl, a heterocyclic radical bonded via a
ring carbon atom and containing up to 20 carbon atoms, or a radical
of the formula R.sub.4--Y--(C.dbd.Z)-- wherein R.sub.4 is
unsubstituted, mono- or disubstituted amino or a heterocyclic
radical containing up to 20 carbon atoms, Y is either not present
or lower alkyl and Z is oxygen, with the proviso that R.sub.1 and
R.sub.2 are not both hydrogen; or [0076] R.sub.1 and R.sub.2
together with the nitrogen atom to which they are attached form a
heterocydic radical containing up to 20 carbon atoms; [0077]
R.sub.3 is a heterocyclic radical containing up to 20 carbon atoms
or an unsubstituted or substituted aromatic radical having up to 20
carbon atoms; [0078] G is C.sub.1-C.sub.3-alkylene; [0079] Q is
--NH--; and [0080] X is either not present or
C.sub.1-C.sub.3-alkylene, with the proviso that a heterocyclic
radical R.sub.3 is bonded via a ring carbon atom if X is not
present; or a salt thereof.
[0081] Special preference is further given to a compound of formula
I, wherein [0082] R.sub.1 and R.sub.2 are each independently of the
other hydrogen, lower alkyl, hydroxy-lower alkyl, N,N-di-lower
alkylamino-lower alkyl, morpholinyl-lower alkyl, tetrahydropyranyl,
or a radical of the formula R.sub.4--Y--(C.dbd.Z)-- wherein R.sub.4
is di-lower alkylamino, pyrrolidinyl, piperidyl, lower
alkyl-piperazinyl, morpholinyl or pyridyl, Y is either not present
or lower alkyl and Z is oxygen, with the proviso that R.sub.1 and
R.sub.2 are not both hydrogen; or [0083] R.sub.1 and R.sub.2
together with the nitrogen atom to which they are attached form a
radical selected from the group consisting of pyrrolidinyl,
piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl and
morpholinyl; [0084] R.sub.3 is phenyl, benzodioxolyl, pyridyl
substituted by hydroxy or lower alkoxy, indolyl substituted by
halogen and lower alkyl, or phenyl substituted by one or more
radicals selected independently of one another from the group
consisting of lower alkyl, hydroxy, lower alkoxy, halogen and
benzyloxy; [0085] G is --CH.sub.2-- or --C(.dbd.O)--; [0086] Q is
--NH-- or --O--, with the proviso that Q is --O-- if G is
--C(.dbd.O)--; and [0087] X is either not present, --CH.sub.2-- or
--CH(CH.sub.3)--, with the proviso that substituted pyridyl or
indolyl R.sub.3 is bonded via a ring carbon atom if X is not
present; or a salt thereof.
[0088] Special preference is further also given to a compound of
formula I, wherein [0089] R.sub.1 and R.sub.2 are each
independently of the other hydrogen, lower alkyl, hydroxy-lower
alkyl or a radical of the formula R.sub.4--Y--(C.dbd.Z)-- wherein
R.sub.4 is di-lower alkylamino, pyrrolidinyl, piperidyl, lower
alkyl-piperazinyl, morpholinyl or pyridyl, Y is either not present
or lower alkyl and Z is oxygen, with the proviso that R.sub.1 and
R.sub.2 are not both hydrogen; or [0090] R.sub.1 and R.sub.2
together with the nitrogen atom to which they are attached form a
radical selected from the group consisting of pyrrolidinyl,
piperidyl, lower alkyl-piperazinyl, di-lower alkyl-piperazinyl and
morpholinyl; [0091] R.sub.3 is phenyl, benzodioxolyl, pyridyl
substituted by hydroxy or lower alkoxy, or phenyl substituted by
one or more radicals selected independently of one another from the
group consisting of lower alkyl, hydroxy, lower alkoxy, halogen and
benzyloxy; [0092] G is --CH.sub.2--; [0093] Q is --NH--; and [0094]
X is either not present, --CH.sub.2-- or --CH(CH.sub.3)--, with the
proviso that substituted pyridyl R.sub.3 is bonded via a ring
carbon atom if X is not present; or a salt thereof.
[0095] Special preference is also given to a compound of formula I
wherein C.sub.1-C.sub.7-alkylene G is attached to the phenyl ring
at position 3 or 4, most especially at position 4.
[0096] Very special preference is further given to a compound of
formula I mentioned in the Examples below, or a salt, especially a
pharmaceutically acceptable salt, thereof.
[0097] Also especially preferred are compounds of formula I,
which--according to the above described tyrosine kinase inhibition
assays--inhibit HER-1, HER-2 and KDR with IC.sub.50 values of less
than 300 nM, most preferably of less than 100 nM.
[0098] Very special preference is further given to compounds of
formula I which inhibit the tyrosine kinase activity of at least
one member of the EGF receptor family together with at least one
member of the VEGF receptor family (dual inhibition of EGF- and
VEGF-receptor family members) with IC.sub.50 values in the range of
0.5 nM to 0.5 .mu.M, especially in the range of 1 nM to 300 nM,
based on the above-described tyrosine kinase inhibition assays.
[0099] Especially preferred are further also compounds of formula I
in which G is C.sub.1-C.sub.7-alkylene since the amine group of
such compounds allows to generate pharmaceutically acceptable salts
of these compounds which in general leads to an increased
solubility and to improved physico-chemical propertiess
[0100] The compounds of formula I or salts thereof are prepared in
accordance with processes known per se (see also EP 682 027, WO
97/02266, WO 97/27199 and WO 98/07726), though not previously
described for the manufacture of the compounds of the formula I,
especially whereby [0101] a) in order to prepare a compound of
formula I, wherein G is C.sub.1-C.sub.7-alkylene and wherein
R.sub.1 and R.sub.2 are each independently of the other hydrogen,
unsubstituted or substituted alkyl or cycloalkyl, or a heterocyclic
radical bonded via a ring carbon atom, with the proviso that
R.sub.1 and R.sub.2 are not both hydrogen, or wherein R.sub.1 and
R.sub.2 together with the nitrogen atom to which they are attached
form a heterocyclic radical, a compound of the formula II ##STR3##
wherein Hal is halogen, G is C.sub.1-C.sub.7-alkylene and R.sub.3,
Q and X have the meanings as defined for a compound of formula I,
is reacted with a compound of the formula III ##STR4## wherein
R.sub.1 and R.sub.2 are each independently of the other hydrogen,
unsubstituted or substituted alkyl or cycloalkyl, or a heterocyclic
radical bonded via a ring carbon atom, with the proviso that
R.sub.1 and R.sub.2 are not both hydrogen, or wherein R.sub.1 and
R.sub.2 together with the nitrogen atom to which they are attached
form a heterocyclic radical; [0102] b) in order to prepare a
compound of formula I, wherein G is C.sub.1-C.sub.7-alkylene and
wherein R.sub.1 is a radical of the formula R.sub.4--Y--(C.dbd.Z)--
wherein R.sub.4 is unsubsbtuted, mono- or disubstituted amino or a
heterocyclic radical, Y is either not present or lower alkyl and Z
is oxygen or sulfur, [0103] (i) a compound of the formula IV
##STR5## wherein Hal is halogen, G is C.sub.1-C.sub.7-alkylene, Z
is oxygen and the remaining substituents and symbols have the
meanings as defined for a compound of formula I according to claim
1, is reacted with a compound of the formula R.sub.4--H wherein
R.sub.4 is unsubstituted, mono- or disubstituted amino or a
heterocyclic radical containing at least one nitrogen ring atom
wherein the heterocyclic radical is attached to the hydrogen atom
of R.sub.4--H via a nitrogen ring atom, or [0104] (ii) a compound
of the formula V ##STR6## wherein G is C.sub.1-C.sub.7-alkylene and
the remaining substituents and symbols have the meanings as defined
for a compound of formula I, is reacted with a compound of the
formula VI ##STR7## wherein R.sub.4 and Y have the meanings as
defined above under formula I and Z is oxygen, whereby a compound
of formula I which results from process b) (i) or (ii) is
optionally converted into the respective compound wherein Z is
sulfur; [0105] c) in order to prepare a compound of formula I,
wherein G is --C(.dbd.O)-- or C.sub.1-C.sub.6-alkylene-C(.dbd.O)--
wherein the carbonyl group is attached to the NR.sub.1R.sub.2
moiety, a compound of formula XI ##STR8## wherein the substituents
and symbols have the meanings as defined for a compound of formula
I, is reacted with a compound of formula XII ##STR9## wherein
R.sub.1 and R.sub.2 have the meanings as defined for a compound of
formula I; or [0106] d) in order to prepare a compound of formula
I, wherein G is C.sub.1-C.sub.7-alkylene, a compound of formula I,
wherein G is --C(.dbd.O)-- or C.sub.1-C.sub.6-alkylene-C(.dbd.O)--
wherein the carbonyl group is attached to the NR.sub.1R.sub.2
moiety, is reacted with a reducing agent to produce the
corresponding compound in which G is C.sub.1-C.sub.7-alkylene;
[0107] whereby functional groups which are present in the starting
compounds of processes a) to d) and are not intended to take part
in the reaction, are present in protected form if necessary, and
protecting groups that are present are cleaved, whereby the said
starting compounds may also exist in the form of salts provided
that a salt-forming group is present and a reaction in salt form is
possible; [0108] and, if so desired, a compound of formula I thus
obtained is converted into another compound of formula I, a free
compound of formula I is converted into a salt, an obtained salt of
a compound of formula I is converted into the free compound or
another salt, and/or a mixture of isomeric compounds of formula I
is separated into the individual isomers. Description of the
Process Variants: Regarding Process a):
[0109] The reaction between a compound of formula II and a compound
of formula III preferably takes place in a suitable inert solvent,
especially N,N-dimethylformamide, in the presence of a base such as
potassium carbonate, at temperatures from room temperature (RT) to
100.degree. C. Altematively, the reaction between a compound of
formula II and a compound of formula III takes place in a suitable
solvent, e.g. lower alcohols, such as ethanol, in the presence of
for example a suitable catalyst such as NaI, preferably at the
reflux temperature of the solvent employed. In a compound of
formula II, Hal is preferably chloro.
Regarding Process b):
[0110] (i) The reaction of a compound of formula IV and a compound
of the formula R.sub.4--H preferably takes place in a suitable
solvent, especially alcohols, e.g. lower alcohols such as
n-butanol, at elevated temperature, preferably near the boiling
temperature of the solvent employed. In a compound of formula IV,
Hal is preferably chloro. [0111] (ii) The reaction between a
compound of formula V and a compound of formula VI preferably takes
place in the presence of
O-(1,2-dihydro-2-oxo-1-pyridyl)-N,N,N'N'-tetramethyluronium-tetraflurobor-
ate (TPTU) and N,N-diisopropylethylamine, or in the presence of
(benzotriazole-1-yloxy)-tris-(dimethylamino)-phosphonium-hexafluoroborate
(BOP) and N-methylmorpholin, in a suitable inert solvent, such as
for example N,N-dimethylformamide, preferably at RT.
[0112] A compound of formula I which results from process b) (i) or
(ii) can be converted into the respective compound of formula I
wherein Z is sulfur, for example, by using an appropriate sulfur
compound, e.g. using reaction with Lawesson's reagent
(2,4-bis-(4-methoxyphenyl)2,4-dithioxo-1,2,3,4-dithia-phosphetan)
in a halogenated carbon hydrate, such as dichloromethane, or an
aprotic solvent, such as toluene or xylene, at temperatures from
about 30.degree. C. to reflux.
Regarding Process c):
[0113] The reaction of a compound of formula XI with a compound of
formula XII preferably takes place in a suitable inert solvent such
as N,N-dimethylformamide and in an inert, for example an argon or
nitrogen, atmosphere, in the presence of diethyl-cyanphosphonate,
preferably at about 0.degree. C.
Regarding process d):
[0114] The reducing agent used in process d) is preferably lithium
aluminium hydride or diisobutyl-aluminium hydride. The reaction
preferably takes place under those conditions described in Example
79 or 141, respectively.
Additional Process Steps
[0115] In the additional process steps, carried out as desired,
functional groups of the starting compounds which should not take
part in the reaction may be present in unprotected form or may be
protected for example by one or more protecting groups. The
protecting groups are then wholly or partly removed according to
one of the known methods. Protecting groups, and the manner in
which they are introduced and removed are described, for example,
in "Protective Groups in Organic Chemistry", Plenum Press, London,
New York 1973, and in "Methoden der organischen Chemie".
Houben-Weyl, 4th edition, Vol. 15/1, Georg-Thieme-Verlag, Stuttgart
1974 and in Theodora W. Greene, "Protective Groups in Organic
Synthesis", John Wiley & Sons, New York 1981. A characteristic
of protecting groups is that they can be removed readily, i.e.
without the occurrence of undesired secondary reactions, for
example by solvolysis, reduction, photolysis or alternatively under
physiological conditions.
[0116] The end products of formula I may however also contain
substituents that can also be used as protecting groups in starting
materials for the preparation of other end products of formula I.
Thus, within the scope of this text, only a readily removable group
that is not a constituent of the particular desired end product of
formula I is designated a "protecting group", unless the context
indicates otherwise.
General Process Conditions
[0117] All process steps described here can be carried out under
known reaction conditions, preferably under those specifically
mentioned, in the absence of or usually in the presence of solvents
or diluents, preferably those that are inert to the reagents used
and able to dissolve them, in the absence or presence of catalysts,
condensing agents or neutralising agents, for example ion
exchangers, typically cation exchangers, for example in the H.sup.+
form, depending on the type of reaction and/or reactants at
reduced, normal, or elevated temperature, for example in the range
from -100.degree. C. to about 190.degree. C., preferably from about
-80.degree. C. to about 150.degree. C., for example at -80 to
-60.degree. C., at RT, at -20 to 40.degree. C., at 0 to 100.degree.
C. or at the boiling point of the solvent used, under atmospheric
pressure or in a closed vessel, if need be under pressure, and/or
in an inert, for example an argon or nitrogen, atmosphere.
[0118] The invention relates also to those embodiments of the
process in which one starts from a compound obtainable at any stage
as an intermediate and carries out the missing steps, or breaks off
the process at any stage, or forms a starting material under the
reaction conditions, or uses said starting material in the form of
a reactive derivative or salt, or produces a compound obtainable by
means of the process according to the invention under those process
conditions, and further processes the said compound in situ. In the
preferred embodiment, one starts from those starting materials
which lead to the compounds described hereinabove as preferred.
[0119] In the preferred embodiment, a compound of formula I is
prepared according to the processes and process steps defined in
the Examples.
[0120] The compounds of formula I, including their salts, are also
obtainable in the form of hydrates, or their crystals can include
for example the solvent used for crystallisation (present as
solvates).
Starting Materials
[0121] New starting materials and/or intermediates, as well as
processes for the preparation thereof, are likewise the subject of
this invention. In the preferred embodiment, such starting
materials are used and reaction conditions so selected as to enable
the preferred compounds to be obtained.
[0122] The starting materials used in the above described processes
a) to b) are known, capable of being prepared according to known
processes (see also EP 682 027, WO 97/02266, WO 97/27199 and WO
98/07726), or commercially obtainable; in particular, they can be
prepared using processes as described in the Examples.
[0123] In the preparation of starting materials, existing
functional groups which do not participate in the reaction should,
if necessary, be protected. Preferred protecting groups, their
introduction and their removal are described above or in the
Examples. In place of the respective starting materials and
transients, salts thereof may also be used for the reaction,
provided that salt-forming groups are present and the reaction with
a salt is also possible. Where the term starting materials is used
hereinbefore and hereinafter, the salts thereof are always
included, insofar as reasonable and possible.
[0124] A compound of formula II can be prepared for example by
reacting a compound of formula VII ##STR10## wherein G is
C.sub.1-C.sub.7-alkylene and R.sub.3, Q and X have the meanings as
defined for a compound of formula I, with e.g. thionyl halogenide,
preferably thionyl choride, in the presence or absence of pyridine,
in an inert solvent, for example toluene or in a 1:1 mixture of
acetonitrile and dioxane, preferably at -10 to 0.degree. C. or at
RT.
[0125] A compound of formula VII can be prepared for example by
reacting a compound of formula VIII ##STR11## wherein R.sub.5 is
lower alkyl, especially methyl or ethyl, and R.sub.3, Q and X have
the meanings as defined for a compound of formula I, with lithium
aluminium hydride, in an inert solvent, especially ethers, e.g.
cyclic ethers such as tetrahydrofuran, preferably at the reflux
temperature of the solvent employed. Alternatively, a compound of
formula VII may be prepared by reacting a compound of formula VIII
with diisobutyl-aluminium hydrde, in an inert solvent, for example
in tetrahydrofuran or in a 1:1 mixture of dichloromethane and
dioxane, preferably at RT.
[0126] A compound of formula VIII wherein Q is --NH-- can be
prepared for example by reacting a compound of formula IX ##STR12##
wherein Hal is halogen, preferably chloro, and R.sub.5 is as
defined above for a compound of formula VIII, with a compound of
the formula H.sub.2N--X--R.sub.3, wherein R.sub.3 and X have the
meanings as defined for a compound of formula I, (i) in a suitable
solvent such as alcohols, especially lower alcohols such as
n-butanol, preferably at the boiling temperature of the solvent
employed or (ii) under catalytic conditions e.g. according to the
Buchwald reaction conditions such as those described in Step 133.1
of Example 133 below.
[0127] A compound of formula VIII wherein Q is --O-- can be
prepared for example by reacting a compound of formula IX, which is
preferably N-protected in the pyrrolo-pyrimidine moiety, with a
compound of the formula HO--X--R.sub.3, wherein R.sub.3 and X have
the meanings as defined for a compound of formula I, in a suitable
inert solvent such as N,N-dimethylformamide and in the presence of
a base such as potassium carbonate, at elevated temperatures,
preferably at around 100.degree. C.
[0128] Alternatively, the carboxylic acid ester of a compound of
formula IX may first be reduced to the corresponding alcohol, e.g.
under conditions described above for the preparation of a compound
of formula VII, and then either be reacted with a compound of the
formula H.sub.2N--X--R.sub.3, e.g. under conditions described above
for the preparation of a compound of formula VIII wherein Q is
--NH--, or be reacted with a compound of the formula
HO--X--R.sub.3, e.g. under conditions described above for the
preparation of a compound of formula VIII wherein Q is --O--.
[0129] A compound of formula IV can be prepared for example by
reacting a compound of formula V with a compound of the formula X
##STR13## wherein Hal is Halogen, preferably chloro, Y has the
meanings as defined above under formula I, and Z is oxygen, in the
presence of triethylamine, in an inert solvent such as e.g.
tetrahydrofuran, preferably at RT.
[0130] A compound of formula XI can be prepared for example by
reacting a compound of formula VIII with LiOH, preferably in a
mixture of dioxane and water, at elevated temperatures, preferably
under those conditions described in Step 141.4 of Example 141
below.
[0131] The remaining starting materials are known, capable of being
prepared according to known processes, or commercially available;
or in particular, they can be prepared using processes as described
in the Examples.
Pharmaceutical Compositions, Methods, and Uses
[0132] The present invention relates also to pharmaceutical
compositions that comprise a compound of formula I, or a
pharmaceutically acceptable salt thereof, as active ingredient and
that can be used especially in the treatment of the diseases
mentioned at the beginning. Compositions for enteral
administration, such as nasal, buccal, rectal or, especially, oral
administration, and for parenteral administration, such as
intravenous, intramuscular or subcutaneous administration, to
warm-blooded animals, especially humans, are especially preferred.
The compositions contain the active ingredient alone or,
preferably, together with a pharmaceutically acceptable carrier.
The dosage of the active ingredient depends upon the disease to be
treated and upon the species, its age, weight, and individual
condition, the individual pharmacokinetic data, and the mode of
administration.
[0133] The present invention also relates to prodrugs of a compound
of formula I that convert in vivo to the compound of formula I as
such. Any reference to a compound of formula I is therefore to be
understood as referring also to the corresponding pro-drugs of the
compound of formula I, as appropriate and expedient.
[0134] The invention relates also to compounds of formula I, or a
pharmaceutically acceptable salt thereof, as such or in the form of
a pharmaceutical composition, for use in a method for the
prophylactic or especially therapeutic treatment of the human or
animal body, to a process for the preparation thereof (especially
in the form of compositions for the treatment of tumours) and to a
method of treating proliferative diseases, primarily tumour
diseases, especially those mentioned above.
[0135] The invention relates also to processes and to the use of
compounds of formula I, or a pharmaceutically acceptable salt
thereof, for the preparation of pharmaceutical compositions which
comprise compounds of formula I, or a pharmaceutically acceptable
salt thereof, as active component (active ingredient).
[0136] If desired, the said pharmaceutical compositions may also
contain further active components, for example cytostatics, and/or
may be used in combination with known therapeutic processes, for
example the administration of hormones or radiation.
[0137] Preference is given for a pharmaceutical composition which
is suitable for administration to a warm-blooded animal, especially
humans or commercially useful mammals suffering from a disease
which responds to an inhibition of a protein tyrosine kinase,
especially to a dual inhibition of EGF- and VEGF-receptor family
members, especially a neoplastic disease, comprising an effective
quantity of a compound of formula I for the inhibition of a protein
tyrosine kinase, especially for the dual inhibition of EGF- and
VEGF-receptor family members, or a pharmaceutically acceptable salt
thereof, together with at least one pharmaceutically acceptable
carrier.
[0138] A pharmaceutical composition for the prophylactic or
especially therapeutic management of neoplastic and other
proliferative diseases of a warm-blooded animal, especially a human
or a commercially useful mammal requiring such treatment,
especially suffering from such a disease, comprising as active
ingredient in a quantity that is prophylactically or especially
therapeutically active against said diseases a compound of formula
I, or a pharmaceutically acceptable salt thereof, is likewise
preferred.
[0139] The pharmaceutical compositions comprise from approximately
1% to approximately 95% active ingredient, single-dose
administration forms comprising in the preferred embodiment from
approximately 20% to approximately 90% active ingredient and forms
that are not of single-dose type comprising in the preferred
embodiment from approximately 5% to approximately 20% active
ingredient. Unit dose forms are, for example, coated and uncoated
tablets, ampoules, vials, suppositories or capsules. Examples are
capsules containing from about 0.05 g to about 1.0 g of active
substance.
[0140] The pharmaceutical compositions of the present invention are
prepared in a manner known per se, for example by means of
conventional mixing, granulating, coating, dissolving or
lyophilising processes.
[0141] The invention relates likewise to a process or a method for
the treatment of one of the pathological conditions mentioned
hereinabove, especially a disease which responds to an inhibition
of a protein tyrosine kinase, especially to a dual inhibition of
EGF- and VEGF-receptor family members, especially a corresponding
neoplastic disease. The compounds of formula I, or pharmaceutically
acceptable salts thereof, can be administered as such or in the
form of pharmaceutical compositions, prophylactically or
therapeutically, preferably in an amount effective against the said
diseases, to a warm-blooded animal, for example a human, requiring
such treatment, the compounds especially being used in the form of
pharmaceutical compositions. In the case of an individual having a
bodyweight of about 70 kg the daily dose administered is from
approximately 0.1 g to approximately 5 g, preferably from
approximately 0.5 g to approximately 2 g, of a compound of the
present invention.
[0142] The present invention relates especially also to the use of
a compound of formula I, or a pharmaceutically acceptable salt
thereof, especially a compound of formula I which is said to be
preferred, or a pharmaceutically acceptable salt thereof, as such
or in the form of a pharmaceutical composition with at least one
pharmaceutically acceptable carrier, for the therapeutic and also
prophylactic management of one or more of the diseases mentioned
hereinabove, preferably a disease which responds to an inhibition
of a protein tyrosine kinase, especially to a dual inhibition of
EGF- and VEGF-receptor family members, especially a neoplastic
disease, in particular if the said disease responds to an
inhibition of a protein tyrosine kinase, especially to a dual
inhibition of EGF- and VEGF-receptor family members.
[0143] The present invention relates especially also to the use of
a compound of formula I, or a pharmaceutically acceptable salt
thereof, especially a compound of formula I which is said to be
preferred, or a pharmaceutically acceptable salt thereof, for the
preparation of a pharmaceutical composition for the therapeutic and
also prophylactic management of one or more of the diseases
mentioned hereinabove, especially a neoplastic disease, in
particular if the disease responds to an inhibition of a protein
tyrosine kinase, especially to a dual inhibition of EGF- and
VEGF-receptor family members.
[0144] A compound of formula I may also be used to advantage in
combination with other antiproliferative agents. Such
antiproliferative agents include, but are not limited to aromatase
inhibitors, antiestrogens, topoisomerase I inhibitors,
topoisomerase II inhibitors, microtubule active agents, alkylating
agents, histone deacetylase inhibitors, farnesyl transferase
inhibitors, COX-2 inhibitors, MMP inhibitors, mTOR inhibitors,
antineoplastic antimetabolites, platin compounds, compounds
decreasing the protein kinase activity and further anti-angiogenic
compounds, gonadorelin agonists, anti-androgens, bengamides,
bisphosphonates, antiproliferative antibodies and temozolomide
(TEMODAL.RTM.).
[0145] The term "aromatase inhibitors" as used herein relates to
compounds which inhibit the estrogen production, i.e. the
conversion of the substrates androstenedione and testosterone to
estrone and estradiol, respectively. The term includes, but is not
limited to steroids, especially exemestane and formestane and, in
particular, non-steroids, especially aminoglutethimide, vorozole,
fadrozole, anastrozole and, very especially, letrozole. Exemestane
can be administered, e.g., in the form as it is marketed, e.g.
under the trademark AROMASIN.TM.. Formestane can be administered,
e.g., in the form as it is marketed, e.g. under the trademark
LENTARON.TM.. Fadrozole can be administered, e.g., in the form as
it is marketed, e.g. under the trademark AFEMA.TM.. Anastrozole can
be administered, e.g., in the form as it is marketed, e.g. under
the trademark ARIMIDEX.TM.. Letrozole can be administered, e.g., in
the form as it is marketed, e.g. under the trademark FEMARA.TM. or
FEMAR.TM.. Aminoglutethimide can be administered, e.g., in the form
as it is marketed, e.g. under the trademark ORIMETEN.TM.. A
combination of the invention comprising an antineoplastic agent
which is an aromatase inhibitor is particularly useful for the
treatment of hormone receptor positive breast tumors.
[0146] The term "antiestrogens" as used herein relates to compounds
which antagonize the effect of estrogens at the estrogen receptor
level. The term includes, but is not limited to tamoxifen,
fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen can
be administered, e.g., in the form as it is marketed, e.g. under
the trademark NOLVADEX.TM.. Raloxifene hydrochloride can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark EVISTA.TM.. Fulvestrant can be formulated as disclosed in
U.S. Pat. No. 4,659,516 or it can be administered, e.g., in the
form as it is marketed, e.g. under the trademark FASLODEX.TM..
[0147] The term "topoisomerase I inhibitors" as used herein
includes, but is not limited to topotecan, irnotecan,
9-nitrocamptothecin and the macromolecular camptothecin conjugate
PNU-166148 (compound A1 in WO99/17804). Irinotecan can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark CAMPTOSAR.TM.. Topotecan can be administered, e.g., in
the form as it is marketed, e.g. under the trademark
HYCAMTIN.TM..
[0148] The term "topoisomerase II inhibitors" as used herein
includes, but is not limited to the antracyclines doxorubicin
(including liposomal formulation, e.g. CAELYX.TM.), epirubicin,
idarubicin and nemorubicin, the anthraquinones mitoxantrone and
losoxantrone, and the podophillotoxines etoposide and teniposide.
Etoposide can be administered, e.g., in the form as it is marketed,
e.g. under the trademark ETOPOPHOS.TM.. Teniposide can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark VM 26-BRISTOL.TM.. Doxorubicin can be administered, e.g.,
in the form as it is marketed, e.g. under the trademark
ADRIBLASTIN.TM.. Epirubicin can be administered, e.g., in the form
as it is marketed, e.g. under the trademark FARMORUBICIN.TM..
Idarubicin can be administered, e.g., in the form as it is
marketed, e.g. under the trademark ZAVEDOS.TM.. Mitoxantrone can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark NOVANTRON.TM..
[0149] The term "microtubule active agents" relates to microtubule
stabilizing and microtubule destabilizing agents including, but not
limited to the taxanes paclitaxel and docetaxel, the vinca
alkaloids, e.g., vinblastine, especially vinblastine sulfate,
vincristine especially vincristine sulfate, and vinorelbine,
discodermolide and epothilones, such as epothilone B and D.
Docetaxel can be administered, e.g., in the form as it is marketed,
e.g. under the trademark TAXOTERE.TM.. Vinblastine sulfate can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark VINBLASTIN R.P..TM.. Vincristine sulfate can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark FARMISTIN.TM.. Discodermolide can be obtained, e.g., as
disclosed in U.S. Pat. No. 5,010,099.
[0150] The term "alkylating agents" as used herein includes, but is
not limited to cyclophosphamide, ifosfamide and melphalan.
Cyclophosphamide can be administered, e.g., in the form as it is
marketed, e.g. under the trademark CYCLOSTIN.TM.. Ifosfamide can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark HOLOXAN.TM..
[0151] The term "histone deacetylase inhibitors" relates to
compounds which inhibit the histone deacetylase and which possess
antiproliferative activity.
[0152] The term "farnestyl transferase inhibitors" relates to
compounds which inhibit the famesyl transferase and which possess
antiproliferative activity.
[0153] The term "COX-2 inhibitors" relates to compounds which
inhibit the cyclooxygenase type 2 enyzme (COX-2) and which possess
antiproliferative activity such as celecoxib (Celebrex.RTM.),
rofecoxib (Vioxx.RTM.) and lumiracoxib (COX189).
[0154] The term "MMP inhibitors" relates to compounds which inhibit
the matrix metalloproteinase (MMP) and which possess
antiproliferative activity.
[0155] The term "mTOR inhibitors" relates to compounds which
inhibit the mammalian target of rapamycin (mTOR) and which possess
antiproliferative activity such as sirolimus (Rapamune.RTM.),
everolimus (Certican.TM.), CCI-779 and ABT578.
[0156] The term "antineoplastic antimetabolites" includes, but is
not limited to 5-fluorouracil, tegafur, capecitabine, cladribine,
cytarabine, fludarabine phosphate, fluorouridine, gemcitabine,
6-mercaptopurine, hydroxyurea, methotrexate, edatrexate and salts
of such compounds, and furthermore ZD 1694 (RALTITREXED.TM.),
LY231514 (ALIMTA.TM.), LY264618 (LOMOTREXOL.TM.) and OGT719.
[0157] The term "platin compounds" as used herein includes, but is
not limited to carboplatin, cisplatin and oxaliplatin. Carboplatin
can be administered, e.g., in the form as it is marketed, e.g.
under the trademark CARBOPLAT.TM.. Oxaliplatin can be administered,
e.g., in the form as it is marketed, e.g. under the trademark
ELOXATIN.TM..
[0158] The term "compounds decreasing the protein kinase activity
and further anti-angiogenic compounds" as used herein includes, but
is not limited to compounds which decrease the activity of e.g. the
Vascular Endothelial Growth Factor (VEGF), the Epidermal Growth
Factor (EGF), c-Src, protein kinase C, Platelet-derived Growth
Factor (PDGF), Bcr-Abl tyrosine kinase, c-kit, Flt-3 and
Insulin-like Growth Factor I Receptor (IGF-IR) and Cyclin-dependent
kinases (CDKs), and anti-angiogenic compounds having another
mechanism of action than decreasing the protein kinase
activity.
[0159] Compounds which decrease the activity of VEGF are especially
compounds which inhibit the VEGF receptor, especially the tyrosine
kinase activity of the VEGF receptor, and compounds binding to
VEGF, and are in particular those compounds, proteins and
monoclonal antibodies generically and specifically disclosed in WO
98/35958 (describing compounds of formula I), WO 00/09495, WO
00/27820, WO 00/59509, WO 98/11223, WO 00/27819, WO 01/55114, WO
01/58899 and EP 0 769 947; those as described by M. Prewett et al
in Cancer Research 59 (1999) 5209-5218, by F. Yuan et al in Proc.
Natl. Acad. Sci. USA, vol. 93, pp. 14765-14770, December 1996, by
Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J. Mordenti
et al in Toxicologic Pathology, vol. 27, no. 1, pp 14-21, 1999; in
WO 00/37502 and WO 94/10202; Angiostatin.TM., described by M. S.
O'Reilly et al, Cell 79, 1994, 315-328; and Endostatin.TM.,
described by M. S. O'Reilly et al, Cell 88, 1997, 277-285;
compounds which decrease the activity of EGF are especially
compounds which inhibit the EGF receptor, especially the tyrosine
kinase activity of the EGF receptor, and compounds binding to EGF,
and are in particular those compounds generically and specifically
disclosed in WO 97/02266 (describing compounds of formula IV), EP 0
564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0
837 063, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and,
especially, WO 96/33980; compounds which decrease the activity of
c-Src include, but are not limited to, compounds inhibiting the
c-Src protein tyrosine kinase activity as defined below and to SH2
interaction inhibitors such as those disclosed in WO97/07131 and
WO97/08193; compounds inhibiting the c-Src protein tyrosine kinase
activity include, but are not limited to, compounds belonging to
the structure classes of pyrrolopyrimidines, especially
pyrrolo[2,3-d]pyrimidines, purines, pyrazopyrimidines, especially
pyrazo[3,4-d]pyrimidines, pyrazopyrimidines, especially
pyrazo[3,4-d]pyrimidines and pyridopyrimidines, especially
pyrdo[2,3-d]pyrimidines. Preferably, the term relates to those
compounds disclosed in WO 96/10028, WO 97/28161, WO97/32879 and
WO97/49706; compounds which decreases the activity of the protein
kinase C are especially those staurosporine derivatives disclosed
in EP 0 296 110 (pharmaceutical preparation described in WO
00/48571) which compounds are protein kinase C inhibitors; further
specific compounds that decrease protein kinase activity and which
may also be used in combination with the compounds of the present
invention are Imatinib (Gleevec.RTM./Glivec.RTM.), PKC412,
Iressa.TM. (ZD1839), PKI166, PTK787, ZD6474, GW2016, CHIR-200131,
CEP-7055/CEP-5214, CP-547632 and KRN-633; anti-angiogenic compounds
having another mechanism of action than decreasing the protein
kinase activity include, but are not limited to e.g. thalidomide
(THALOMID), celecoxib (Celebrex), SU5416 and ZD6126.
[0160] The term "gonadorelin agonist" as used herein includes, but
is not limited to abarelix, goserelin and goserelin acetate.
Goserelin is disclosed in U.S. Pat. No. 4,100,274 and can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark ZOLADEX.TM.. Abarelix can be formulated, eg. as disclosed
in U.S. Pat. No. 5,843,901.
[0161] The term "anti-androgens" as used herein includes, but is
not limited to bicalutamide (CASODEX.TM.), which can be formulated,
e.g. as disclosed in U.S. Pat. No. 4,636,505.
[0162] The term "bengamides" relates to bengamides and derivatives
thereof having aniproliferative properties.
[0163] The term "bisphosphonates" as used herein includes, but is
not limited to etridonic acid, clodronic acid, tiludronic acid,
pamidronic acid, alendronic acid, ibandronic acid, risedronic acid
and zoledronic acid. "Etridonic acid" can be administered, e.g., in
the form as it is marketed, e.g. under the trademark DIDRONEL.TM..
"Clodronic acid" can be administered, e.g., in the form as it is
marketed, e.g. under the trademark BONEFOS.TM.. "Tiludronic acid"
can be administered, e.g., in the form as it is marketed, e.g.
under the trademark SKELID.TM.. "Pamidronic acid" can be
administered, e.g., in the form as it is marketed, e.g. under the
trademark AREDIA.TM.. "Alendronic acid" can be administered, e.g.,
in the form as it is marketed, e.g. under the trademark
FOSAMAX.TM.. "Ibandronic acid" can be administered, e.g., in the
form as it is marketed, e.g. under the trademark BONDRANAT.TM..
"Risedronic acid" can be administered, e.g., in the form as it is
marketed, e.g. under the trademark ACTONEL.TM.. "Zoledronic acid"
can be administered, e.g., in the form as it is marketed, e.g.
under the trademark ZOMETA.TM..
[0164] The term "antiproliferative antibodies" as used herein
includes, but is not limited to trastuzumab (Herceptint.TM.),
Trastuzumab-DM1, erlotinib (Tarceva.TM.), bevacizumab
(Avastin.TM.), rituximab (Rituxan.RTM.), PRO64553 (anti-CD40) and
2C4 Antibody.
[0165] For the treatment of AML, compounds of formula I can be used
in combination with standard leukemia therapies, especially in
combination with therapies used for the treatment of AML. In
particular, compounds of formula I can be administered in
combination with e.g. farnesyltransferase inhibitors and/or other
drugs used for the treatment of AML, such as Daunorubicin,
Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin,
Carboplatinum and PKC412.
[0166] The structure of the active agents identified by code nos.,
generic or trade names may be taken from the actual edition of the
standard compendium "The Merck Index" or from databases, e.g.
Patents International (e.g. IMS World Publications).
[0167] The above-mentioned compounds, which can be used in
combination with a compound of formula I, can be prepared and
administered as described in the art such as in the documents cited
above.
EXAMPLES
[0168] The following Examples serve to illustrate the invention
without limiting its scope.
[0169] Temperatures are measured in degrees Celsius. Unless
otherwise indicated, the reactions take place at RT.
[0170] The R.sub.1 values which indicate the ratio of the distance
moved by each substance to the distance moved by the eluent front
are determined on silica gel thin-layer plates (Merck, Darmstadt,
Germany) by thin-layer chromatography using the respective named
solvent systems.
[0171] If not otherwise indicated, the analytical HPLC conditions
are as follows: [0172] Column: (250.times.4.6 mm) packed with
reversed-phase material C18-Nucleosil (5 .mu.m mean particle size,
with silica gel covalently derivatized with octadecylsilanes,
Macherey & Nagel, Duren, Germany). Detection by UV absorption
at 215 nm. The retention times (t.sub.R) are given in minutes. Flow
rate: 1 ml/min. [0173] Gradient: 20%.fwdarw.100% a) in b) for 14
min+5 min 100% a). a): Acetonitrile+0.05% TFA; b): water+0.05%
TFA.
[0174] The short forms and abbreviations used have the following
definitions: [0175] conc. concentrated [0176] DMF
N,N-dimethylformamide [0177] Elem. anal. elemental analysis [0178]
Et ethyl [0179] EtOAc ethyl acetate [0180] MS-ES mass spectroscopy
(electron spray) [0181] h hour(s) [0182] Me methyl [0183] MeOH
methanol [0184] min minute(s) [0185] m.p. melting point [0186] RT
room temperature [0187] TFA trifluoroacetic acid [0188] THF
tetrahydrofuran (distilled over Na/benzophenone) [0189] TLC
thin-layer chromatography [0190] t.sub.R retention times
Example 1
(3Chloro-4-fluoro-phenyl)-[6-(4-dimethylaminomethyl-phenyl)-7H-pyrrolo[2,3-
-d]pyrimidin-4-yl]-amine
[0191] A mixture of 200 mg (0.5 mmol) crude
(3-chloro-4-fluoro-phenyl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-amine in 15 ml absolute ethanol is treated with 0.8
ml (5 mmol) of a 33% solution of dimethylamine in ethanol (Fluka,
Buchs, Switzerland) and then heated under reflux for 1 h. The
almost clear solution is cooled and the solvent evaporated. The
residue is dissolved in a mixture of dichloromethane and ethanol
(95:5), washed with water, dried over sodium sulfate and the
solvent evaporated. Purification of the crude material through
flash chromatography using first dichloromethane/ethanol 95:5 plus
1% conc. ammonia and then dichloromethane/ethanol 9:1 plus 1% conc.
ammonia gives the title compound; m.p. 274-276.degree. C.;
MS-ES.sup.+: (M+H).sup.+=396.
Step 1.1:
4-[4-(3-Chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin--
6-yl]-benzoic acid ethyl ester
[0192] 3.6 g (12 mmol)
4-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzoic acid ethyl
ester (WO 97/02266) are suspended in 80 ml n-butanol and treated
with 3.5 g (24 mmol) 3-chloro-4-fluoro-aniline. The mixture is
heated to 145.degree. C. under stirring. After 30 min a clear brown
solution is obtained which turns into a thick suspension after 2 h.
After a total of 3 h the reaction mixture is cooled in an ice bath
and the product collected by filtration; m.p.>300.degree. C.;
R.sub.f (dichloromethane/ethanol 95:5 plus 1% conc. ammonia)=0.29;
HPLC t.sub.R=11.66 min.
Step 1.2:
{4-[4-(3-Chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-
-6-yl]-phenyl}-methanol
[0193] 570 mg (15 mmol) lithium aluminium hydride are suspended in
150 ml dry THF at RT.
4-[4-(3-Chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ben-
zoic acid ethyl ester (1.23 g, 3 mmol) are added and the resulting
mixture is heated to reflux for 1 h. The mixture is cooled in an
ice bath and treated sequentially with water (0.57 ml), 15% sodium
hydroxide solution (0.57 ml) and water (1.71 ml). The solid
aluminum complex is removed by filtration (Hyflo Super Cel.RTM.;
Fluka, Buchs, Switzerland), the filtrate dried over sodium sulfate
and the solvent evaporated. The residue was suspended in water,
filtered and dried to give the title compound; m.p.>300.degree.
C.; HPLC t.sub.R=9.14 min.
Step 1.3:
(3-Chloro-4-fluoro-phenyl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo-
[2,3-d]pyrimidin-4-yl]-amine
[0194] 184 mg (0.5 mmol)
{4-[4-(3-Chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ph-
enyl}-methanol are suspended in 15 ml toluene. Pyridine (44 .mu.l,
0.55 mmol) and thionyl chloride (40 .mu.l, 0.55 mmol) are added and
the mixture is stirred at RT for 16 h. A second portion of the same
amounts of pyridine and thionyl chloride are then added and the
mixture stirred for 1 additional hour. The solvent is evaporated
and the residue suspended in water containing a small amount of
sodium bicarbonate (pH.about.8). After filtration, the product was
thoroughly washed with water and ether and dried to give crude
title compound; m.p.>300.degree. C.; R.sub.f
(dichloromethane/ethanol 95:5 plus 1% conc. ammonia)=0.42; HPLC
t.sub.R=11.33 min.
Examples 2-8d
[0195] The following Examples are synthesized from
(3-chloro-4-fluoro-phenyl)[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyr-
imidin-4-yl]-amine using an analogous procedure described in
Example 1: TABLE-US-00001 Example m.p. MS-ES.sup.+: TLC HPLC Number
Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 2
(3-Chloro-4-fluoro-phenyl)-[6-(4- 285-287 424 0.32.sup.a 8.54
diethylaminomethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]- amine
3 (3-Chloro-4-fluoro-phenyl)-{6-[4- 266-268 465 0.42.sup.b 7.7
(4-ethyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 4 (3-Chloro-4-fluoro-phenyl)-[6-(4- 268-270
422 0.45.sup.b 8.4 pyrrolidin-1-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 5
(3-Chloro-4-fluoro-phenyl)-{6-[4- 264-266 451 0.33.sup.b 7.5
(4-methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 6 (3-Chloro-4-fluoro-phenyl)-[6-(4- 267-269
436 0.40.sup.b 8.66 piperidin-1-ylmethyl-phenyl)-7H-
pyrrolo[2,3-d]pyrimidin-4-yl]- amine 7
(3-Chloro-4-fluoro-phenyl)-[6-(4- 298-300 438 0.21.sup.a 8.07
morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 8 (3-Chloro-4-fluoro-phenyl)-{6-[4- 261-263 465 0.35.sup.b
7.53 (3,5-dimethyl-piperazin-1- ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-yl}- amine 8a
(3-Chloro-4-fluoro-phenyl)-(6-{4- 288-290 452 0.43.sup.c 7.68
[(tetrahydro-pyran-4-ylamino)- methyl]-phenyl}-7H-pyrrolo[2,3-
d]pyrimidin-4-yl)-amine 8b (3-Chloro-4-fluoro-phenyl)-(6-{4-
224-226 481 0.3.sup.d 7.22 [(2-morpholin-4-yl-ethylamino)-
methyl]-phenyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-amine 8c
N-{4-[4-(3-Chloro-4-fluoro- 229-231 467 0.18.sup.d 7.41
phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-N',N'-
diethyl-ethane-1,2-diamine 8d (3-Chloro-4-fluoro-phenyl)-{6-[4-
282-284 410 0.72.sup.d 8.14 (isopropylamino-methyl)-
phenyl]-7H-pyrrolo[2,3- d]pyrimidin-4-yl}-amine
.sup.aDichloromethane/ethanol 95:5 + 1% conc. ammonia
.sup.bDichloromethane/ethanol 9:1 + 1% conc. ammonia
.sup.cDichloromethane/ethanol 9:1 + 2% conc. ammonia
.sup.dDichloromethane/ethanol 7:3 + 1% conc. ammonia
Example 9
{6-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrro[2,3-d]pyrimidin-4-y-
l}-((R)-1-phenyl-ethyl)-amine
[0196] A mixture of 10.8 g (30 mmol)
[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-
-ethyl)-amine in 450 ml DMF is treated with 6.8 ml (63 mmol)
N-methylpiperazine and 20.7 g (150 mmol) anhydrous potassium
carbonate and the mixture heated to 65.degree. C. for 1 hour. The
reaction mixture is cooled and the inorganic salts removed by
filtration (Hyflo Super Cel.RTM.; Fluka, Buchs, Switzerland). The
DMF is evaporated under reduced pressure and the residue purified
through flash chromatography using first dichloromethane/ethanol
9:1 and then dichloromethane/ethanol 9:1 plus 1% conc. ammonia.
Crystallization of the pure fractions from THF (20 ml) and hexanes
(80 ml) gives the title compound; m.p. 248-250.degree. C.;
MS-ES.sup.+: (M+H).sup.+=427.
Step 9.1:
4-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]--
benzoic acid ethyl ester
[0197] 1.8 g (6 mmol)
4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzoic acid ethyl
ester (WO 97/02266) are suspended in 40 ml n-butanol and treated
with 1.5 ml (12 mmol) (R)-phenethylamine. The mixture is heated to
145.degree. C. under stirring. After 3 h a clear brown solution is
obtained which is treated with a second portion of
(R)-phenethylamine (0.75 ml, 6 mmol). After stirring for additional
2 h the reaction mixture is cooled in an ice bath and the title
compound filtered and washed with cold n-butanol and ether; m.p.
288-290.degree. C.; MS-ES.sup.+: (M+H).sup.+=387.
Step 9.2:
{4-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-
-phenyl}-methanol
[0198] 570 mg (15 mmol) lithium aluminum hydride are suspended in
150 ml dry THF at RT. 1.23 g (3 mmol)
4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzoic
acid ethyl ester are added and the mixture heated to reflux for 1
h. The mixture is cooled in an ice bath and treated sequentially
with water (0.57 ml), 15% sodium hydroxide solution (0.57 ml) and
water (1.71 ml). The solid aluminum complex is removed by
filtration (Hyflo Super Cel.RTM.; Fluka, Buchs, Switzerland), the
filtrate dried over sodium sulfate evaporated. The residue is
suspended in water, filtered and dried to give the title compound;
m.p.>300.degree. C.; R.sub.f (dichloromethane/ethanol 9:1 plus
1% conc. ammonia)=0.43; HPLC t.sub.R=8.71 min.
Step 9.3:
[6-(4-Chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-
-1-phenyl-ethyl)-amine
[0199] A solution of thionyl chloride (25.7 ml, 0.328 mol) in 180
ml of toluene is cooled to -10.degree. C. Solid
{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}--
methanol (11.3 g, 0.0328 mol) is added in 8 portions over a range
of 1 h. The temperature is then increased slowly to 0.degree. C.
and the mixture stirred for 2 h. The cold reaction mixture is
filtered and the solid washed with toluene and ether. The crude
product is suspended in water and treated with saturated sodium
bicarbonate solution until the mixture turns basic. The mixture is
stirred well for about 10 min and filtered. The solid is thoroughly
washed with water and dried under reduced pressure to give the
title compound; m.p.>320.degree. C.; R.sub.f
(dichloromethane/ethanol 9:1)=0.46; HPLC t.sub.R=10.63 min;
MS-ES.sup.+: (M+H).sup.+=363.
Examples 10-16g
[0200] The following Examples are synthesized from
[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-
-ethyl)-amine using an analogous procedure described in Example 9:
TABLE-US-00002 Example m.p. MS-ES.sup.+: TLC HPLC Number Name
[.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 10
[6-(4-Diethylaminomethyl- 246-248 400 0.5.sup.a 7.96
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-((R)-1-phenyl-
ethyl)-amine 11 {6-[4-(4-Ethyl-piperazin-1- 245-247 441 0.38.sup.a
7.14 ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-yl}-
((R)-1-phenyl-ethyl)-amine 12 ((R)-1-Phenyl-ethyl)-[6-(4- 254-256
398 0.5.sup.a 7.91 pyrrolidin-1-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 13
[6-(4-Dimethylaminomethyl- 241-243 427 0.39.sup.a 6.35
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-((R)-1-phenyl-
ethyl)-amine 14 ((R)-1-Phenyl-ethyl)-[6-(4- 246-248 412 0.53.sup.a
8.1 piperidin-1-ylmethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 15 [6-(4-Morpholin-4-ylmethyl- 263-265 414 0.6.sup.a 7.5
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-((R)-1-phenyl-
ethyl)-amine 16 {6-[4-(3,5-Dimethyl-piperazin-1- 208-210 441
0.3.sup.a 7.16 ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-yl}-
((R)-1-phenyl-ethyl)-amine 16a (6-{4-[(2-Morpholin-4-yl- 222-224
457 0.46.sup.b 6.66 ethylamino)-methyl]-phenyl}-7H-
pyrrolo[2,3-d]pyrimidin-4-yl)- ((R)-1-phenyl-ethyl)-amine 16b
((R)-1-Phenyl-ethyl)-(6-{4- 253-255 428 0.42.sup.c 7.18
[(tetrahydro-pyran-4-ylamino)- methyl]-phenyl}-7H-pyrrolo[2,3-
d]pyrimidin-4-yl)-amine 16c N,N-Diethyl-N'-{4-[4-((R)-1- 145-150
443 0.55.sup.b 6.73 phenyl-ethylamino)-7H-
pyrrolo[2,3-d]pyrimidin-6-yl]- benzyl}-ethane-1,2-diamine 16d
{6-[4-(tert-Butylamino-methyl)- >300 400 0.53.sup.c 7.68
phenyl]-7H-pyrrolo[2,3- d]pyrimidin-4-yl}-((R)-1-phenyl-
ethyl)-amine 16e {6-[4-(Isopropylamino-methyl)- 266-268 386
0.5.sup.c 7.66 phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-((R)-1-phenyl- ethyl)-amine 16f
[6-(4-Ethylaminomethyl-phenyl)- 236-238 372 0.33.sup.c 7.41
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- ((R)-1-phenyl-ethyl)-amine 16g
[6-(4-Methylaminomethyl- 234-236 358 0.1.sup.c 7.27
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-((R)-1-phenyl-
ethyl)-amine .sup.aDichloromethane/ethanol 9:1 + 1% conc. ammonia
.sup.bDichloromethane/ethanol 7:3 + 2% conc. ammonia
.sup.cDichloromethane/ethanol 9:1 + 2% conc. ammonia
Example 17
(4-Benzyloxy-phenyl)-[6-(4-dimethylaminomethyl-phenyl)-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-amine
[0201] A mixture of 220 mg (0.5 mmol) crude
(4-benzyloxy-phenyl)[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-
-4-yl]-amine in 15 ml absolute ethanol is treated with 0.8 ml (5
mmol) of a 33% solution of dimethylamine in ethanol (Fluka, Buchs,
Switzerland) and then heated under reflux for 1 h. The resulting
solution is cooled and the solvent evaporated. The residue is
dissolved in a mixture of dichloromethane and ethanol (95:5),
washed with water, dried over sodium sulfate and the solvent
evaporated. The solid material is then suspended in ether stirred
for 5 min and filtered. Purification of the crude material through
flash chromatography using dichloromethane/ethanol 9:1 plus 1%
conc. ammonia gives the title compound; m.p. 272-274.degree. C.;
MS-ES.sup.+: (M+H).sup.+=450.
Step 17.1
(4-Benzyloxy-phenyl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d-
]pydmidin-4-yl]-amine
[0202] This material is prepared in an analogous procedure as
described in steps 1.1 to 1.3; m.p.>300.degree. C.; HPLC
t.sub.R=12.19 min; MS-ES.sup.+: (M+H).sup.+=441.
Examples 18-24
[0203] The following Examples are synthesized from
(4-benzyloxy-phenyl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidi-
n-4-yl]-amine using an analogous procedure described in Example 17:
TABLE-US-00003 Example m.p. MS-ES.sup.+: TLC HPLC Number Name
[.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 18
(4-Benzyloxy-phenyl)-{6-[4-(4- 256-258 505 0.28.sup.a 8.37
methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 19 (4-Benzyloxy-phenyl)-[6-(4- 256-258 490
0.5.sup.b 9.4 piperidin-1-ylmethyl-phenyl)-7H-
pyrrolo[2,3-d]pyrimidin-4-yl]- amine 20 (4-Benzyloxy-phenyl)-[6-(4-
272-274 492 0.25.sup.b 9.03 morpholin-4-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 21
(4-Benzyloxy-phenyl)-[6-(4- 271-273 478 0.15.sup.a 9.30
diethylaminomethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]- amine
22 (4-Benzyloxy-phenyl)-{6-[4-(4- 256-258 519 0.6.sup.b 8.37
ethyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 23 (4-Benzyloxy-phenyl)-[6-(4- 265-267 476
0.44.sup.b 9.23 pyrrolidin-1-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 24
(4-Benzyloxy-phenyl)-{6-[4-(3,5- 269-271 519 0.3.sup.b 8.32
dimethyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine .sup.aDichloromethane/ethanol 95:5 + 1%
conc. ammonia .sup.bDichloromethane/ethanol 9:1 + 1% conc.
ammonia
Example 25
[6-(3-Dimethylaminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R-1-p-
henyl-ethyl)-amine
[0204] A mixture of 240 mg (0.5 mmol) crude
[6-(3-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-
-ethyl)-amine in 15 ml ethanol is treated with 0.8 ml (5 mmol) of a
33% solution of dimethylamine in ethanol (Fluka, Buchs,
Switzerland) and then heated under reflux for 1 h. The clear
solution is cooled and the solvent evaporated. The residue is
purified with flash chromatography using dichloromethane/ethanol
95:5 and then dichloromethane/ethanol 9:1 plus 1% conc. ammonia to
give the title compound; m.p. 108-110.degree. C.; MS-ES.sup.+:
(M+H).sup.+=372.
Step 25.1:
{3-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-phenyl}methanol
[0205] This material is prepared in an analogous procedure as
described in steps 9.1 to 9.2; m.p. 217-219.degree. C.;
MS-ES.sup.+: (M+H).sup.+=345.
Step 25.2:
[6-(3-Chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R-
)-1-phenyl-ethyl)-amine
[0206] A mixture of 688 mg (2 mmol)
{3-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}--
methanol and 578 mg (2.2 mmol) triphenylphosphine in 60 ml
dichloromethane is treated at 0.degree. C. with 293 mg (2.2 mmol)
N-chlorosuccinimide. After stirring 1 h at 0.degree. C. all the
material has gone into solution. The solvent is evaporated and the
title compound purified with flash chromatography using
dichloromethane/ethanol 95:5 (the title compound is contaminated
with a small amount of triphenylphosphine oxide); R.sub.f
(dichloromethane/ethanol 95:5)=0.35; MS-ES.sup.+:
(M+H).sup.+=363.
Examples 26-32
[0207] The following Examples are synthesized from
[6-(3-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-
-ethyl)-amine using an analogous procedure as described in Example
25: TABLE-US-00004 Example m.p. MS-ES.sup.+: TLC HPLC Number Name
[.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 26
[6-(3-Diethylaminomethyl- 110-113 400 0.6.sup.a 8.15
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-((R)-1-phenyl-
ethyl)-amine 27 {6-[3-(4-Ethyl-piperazin-1- 128-130 441 0.34.sup.b
7.3 ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-yl}-
((R)-1-phenyl-ethyl)-amine 28 ((R)-1-Phenyl-ethyl)-[6-(3- 90-92 398
0.50.sup.b 7.97 pyrrolidin-1-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 29
{6-[3-(4-Methyl-piperazin-1- 112-115 427 0.27.sup.b 7.25
ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-yl}-
((R)-1-phenyl-ethyl)-amine 30 ((R)-1-Phenyl-ethyl)-[6-(3- 108-110
412 0.6.sup.b 8.19 piperidin-1-ylmethyl-phenyl)-7H-
pyrrolo[2,3-d]pyrimidin-4-yl]- amine 31 [6-(3-Morpholin-4-ylmethyl-
242-243 414 0.28.sup.a 7.8 phenyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-yl]-((R)-1-phenyl- ethyl)-amine 32
{6-[3-(3,5-Dimethyl-piperazin-1- 128-130 441 0.3.sup.b 7.18
ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-yl}-
((R)-1-phenyl-ethyl)-amine .sup.aDichloromethane/ethanol 95:5 + 1%
conc. ammonia .sup.bDichloromethane/ethanol 9:1 + 1% conc.
ammonia
Example 33
(3-Chloro-4-fluoro-phenyl)-[6-(3-dimetylaminomethyl-phenyl)-7H-pyrrolo[2,3-
-d]pyrimidin-4-yl]-amine
[0208] The compound is synthesized analogously to Example 1
starting with
(3-chloro-4-fluoro-phenyl)-[6-(3-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-amine; m.p. 218-220.degree. C.; MS-ES.sup.+:
(M+H).sup.+=396.
Step 33.1:
(3-Chloro-4-fluoro-phenyl)-[6-(3-chloromethyl-phenyl)-7H-pyrrol-
o[2,3-d]pyrimidin-4-yl]-amine
[0209] The title compound is prepared in an analogous procedure as
described in steps 1.1 to 1.3; R.sub.f (dichloromethane/ethanol
95:5 plus 1% conc. ammonia)=0.45; MS-ES.sup.+: (M+H).sup.+=387.
Examples 34-39
[0210] The following Examples are synthesized from
(3-chloro-4-fluorophenyl)-[6-(3-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyr-
imidin-4-yl]-amine using an analogous procedure as described in
Example 33: TABLE-US-00005 Example m.p. MS-ES.sup.+: TLC HPLC
Number Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 34
(3-Chloro-4-fluoro-phenyl)-[6- 210-212 424 0.32.sup.a 8.76
(3-diethylaminomethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 35 (3-Chloro-4-fluoro-phenyl)-{6- 238-240 465 0.4.sup.b 7.7
[3-(4-ethyl-piperazin-1- ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-yl}- amine 36
(3-Chloro-4-fluoro-phenyl)-[6- 238-240 422 0.45.sup.b 8.44
(3-pyrrolidin-1-ylmethyl- phenyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-yl]-amine 37 (3-Chloro-4-fluoro-phenyl)-{6- 221-223
451 0.33.sup.b 7.6 [3-(4-methyl-piperazin-1- ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-yl}- amine 38
(3-Chloro-4-fluoro-phenyl)-[6- 233-235 436 0.45.sup.b 8.75
(3-piperidin-1-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-
yl]-amine 39 (3-Chloro-4-fluoro-phenyl)-[6- 290-292 438 0.21.sup.a
8.15 (3-morpholin-4-ylmethyl- phenyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-yl]-amine .sup.aDichloromethane/ethanol 95:5 + 1%
conc. ammonia .sup.bDichloromethane/ethanol 9:1 + 1% conc.
ammonia
Example 40
N-{4-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzyl}-
-2-piperidin-1-yl-acetamide
[0211] A mixture of 80 mg (0.19 mmol)
2-chloro-N-{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3d]pyrimidin-6-yl-
]-benzyl}acetamide in 1.5 ml n-butanol is treated with 47 .mu.l
(0.48 mmol) piperidine and then heated to 100.degree. C. for 2 h.
The clear solution is cooled and the solvent evaporated. The
residue is purified with flash chromatography using a mixture of
ethyl acetate/methanol with increasing concentrations of methanol
starting with 100:2.5 and ending with 10:1. The title compound is
obtained as a colorless powder; m.p. 194-196.degree. C.;
MS-ES.sup.+: (M+H).sup.+=469.
Step 40.1: 2-Amino-5-(4-cyano-phenyl)-1H-pyrrole-3-carboxylic acid
ethyl ester
[0212] A mixture of 42.53 g (0.255 mol) carbamimidoyl-acetic acid
ethyl ester hydrochloride in 70 ml absolute ethanol is treated at 0
to 5.degree. C. with 95.3 ml of a 21% sodium ethoxide solution in
ethanol (0.255 mol) and stirred 5 min at 0 to 5.degree. C.
4-Bromoacetyl-benzonitrile (28.6 g, 0.128 mol) is then added in
portions over 20 min at 0 to 5.degree. C. Stirring is continued at
this temperature for 5 min then the ice bath is removed and the
yellow suspension is stirred over night at RT. The solid is
filtered off, washed with ethanol and ether and re-suspended in 450
ml actonitrile. The mixture is heated for 5 min under reflux,
filtered while still hot and then cooled in an ice bath. The title
compound is collected by succion and dried. Flash chromatography
(dichtoromethane/ethyl acetate mixture) of the mother liquors gives
an additional crop of the title compound as a yellow solid; m.p.
228-229.degree. C.; MS-ES.sup.+: (M+H).sup.+=254.
Step 40.2:
4-(4-Hydroxy-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzonitrile
[0213] A mixture of 36.6 g (0.143 mol)
2-amino-5-(4-cyano-phenyl)-1H-pyrrole-3-carboxylic acid ethyl
ester, 140 ml DMF, 305 ml formamide and 14.6 ml 85% formic acid is
heated for 16 h at 150.degree. C. The resulting yellow suspension
is cooled to 10.degree. C. and filtered. The solid is washed with
methanol (120 ml) and ether (150 ml) and dried. The title compound
is obtained as yellowish crystals; m.p.>410.degree. C.;
MS-ES.sup.+: (M+H).sup.+=254.
Step 40.3:
4-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-4-6-yl)-benzonitrile
[0214] 4-(4-Hydroxy-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzonitrile
(2,36 9. 0.01 mol) are suspended in 40 ml acetonitril and 4.99 ml
(0.02 mol) 4 N hydrochloric acid solution in dioxane. After
addition of 3.66 ml (0.04 mol) phosphorus oxichloride the mixture
is heated under reflux for 3 days. The solid is filtered off and
the mother liquor evaporated. The residue and the solid are
dissolved in 30 ml DMF at 60.degree. C. and 25 ml of a conc. sodium
bicarbonate solution and 25 ml water are added and the resulting
suspension cooled, filtered and the solid washed with water. The
title compound is dried at 100.degree. C. for 6 h under reduced
pressure; m.p. 296-297.degree. C.; HPLC t.sub.R=11.59 min.
Step 40.4:
4-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-
-benzonitrile
[0215] A mixture of 1.27 g (5 mmol)
4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzonitrile, 1.4 ml
(10 mol) triethylamine and 0.955 ml (7.5 mmol)
R(+)-1-phenyl-ethylamine in 25 ml dioxane is heated under reflux
for 24 h. A second portion of R(+)-1-phenyl-ethylamine (0.32 ml,
2.5 mmol) is added and heating is continued for 24 h. After
addition of a third portion of R(+)-1-phenyl-ethylamine (0.32 ml,
2.5 mmol) and additional 24 h the reaction mixture is cooled to
10.degree. C. and the title compound filtered off and washed with
dioxane. From the mother liquor a second crop is obtained after
concentration of the solution; m.p. 333-336.degree. C.;
MS-ES.sup.+: (M+H).sup.+=340.
Step 40.5:
[6-(4-Aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-
-1-phenyl-ethyl)-amine
[0216] Raney-Nickel (0.1 9) catalyzed hydrogenation of 0.206 g (0.6
mmol)
4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzonitr-
ile in a mixture of 5% ammonia in methanol (20 ml) and THF (4 ml)
for 6 h at atmospheric pressure followed by filtration and
evaporation of the solvent gives the title compound; m.p.
253-256.degree. C.; MS-ES.sup.+: (M+H)+=344.
Step 40.6:
2-Chloro-N-{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyr-
imidin-6-yl]-benzyl}-acetamide
[0217] A mixture of 0.21 g (0.6
mmol)[6-(4-aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-ph-
enyl-ethyl)-amine and 94 .mu.l (0.67 mmol) triethylamine in 5 ml
dry THF is treated dropwise with a solution of chloro-acetyl
chloride (51 .mu.l, 0.64 mmol) in 0.5 ml of dry THF at RT. After
stirring for 30 min small amounts of insoluble material is removed
by filtration and the filtrate is evaporated. The residue is
purified by flash chromatography using ethyl acetate/methanol 100:2
to 100:4 as eluent. The title compound is obtained as light brown
solid HPLC t.sub.R=9.36 min; MS-ES.sup.+: (M+H).sup.+=420.
Examples 41-45
[0218] The following Examples are synthesized from
2-chloro-N-{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-y-
l]-benzyl}-acetamide using an analogous procedure as described in
Example 40: TABLE-US-00006 Example m.p. MS-ES.sup.+: TLC HPLC
Number Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 41
N-{4-[4-((R)-1-Phenyl- 196-198 455 0.25.sup.a 7.92
ethylamino)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-2-
pyrrolidin-1-yl-acetamide 42 2-Morpholin-4-yl-N-{4-[4-((R)- 199-202
471 0.28.sup.a 7.78 1-phenyl-ethylamino)-7H-
pyrrolo[2,3-d]pyrimidin-6-yl]- benzyl}-acetamide 43
2-(4-Methyl-piperazin-1-yl)-N- 150-152 484 0.29.sup.b 7.45
{4-[4-((R)-1-phenyl- ethylamino)-7H-pyrrolo[2,3-
d]pyrimidin-6-yl]-benzyl}- acetamide 44
2-Dimethylamino-N-{4-[4-((R)- 263-266 429 0.21.sup.a 7.64
1-phenyl-ethylamino)-7H- pyrrolo[2,3-d]pyrimidin-6-yl]-
benzyl}-acetamide 45 2-(4-Ethyl-piperazin-1-yl)-N-{4- 121-124 498
0.26.sup.b 7.66 [4-((R)-1-phenyl-ethylamino)-
7H-pyrrolo[2,3-d]pyrimidin-6-yl]- benzyl}-acetamide
.sup.adichloromethane/methanol 9:1
.sup.bdichloromethane/methanol/conc. ammonia 90:10:1
Example 46
N-{4-[4-(3-Chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-b-
enzyl}-2-dimethylamino-acetamide
[0219]
2-Chloro-N-{4-[4-(3-chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]-
pyrimidin-6-yl]-benzyl}-acetamide (100 mg, 0.225 mmol) in 2 ml
n-butanol and 0.12 ml (0.67 mmol) 5.6 N dimethylamine in ethanol
(Fluka, Buchs, Switzerland) is stirred and heated to 100.degree. C.
for 6 h. The mixture is cooled, filtered and the solid re-suspended
in 3 ml hot ethanol. After cooling the title compound is collected
by filtration, washed with ethanol and dried; m.p. 278-282; R.sub.f
(ethyl acetate/methanol 8:2)=0.14; HPLC t.sub.R=8.04 min;
MS-ES.sup.+: (M+H).sup.+=453.
Step 46.1:
2-Chloro-N-{4-[4-(3-chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-
-d]pyrimidin-6-yl]-benzyl}-acetamide
[0220] This compound is synthesized using an analogous sequence as
described for
2-chloro-N-{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-y-
l]-benzyl}-acetamide (steps 40.4 to 40.6); m.p. 320-325.degree. C.;
R.sub.f (dichloromethane/methanol/conc. ammonia 90:10:1)=0.39;
MS-ES.sup.+: (M+H).sup.+=444.
Examples 47-50
[0221] The following Examples are synthesized from
2-chloro-N-{4-[4-(3-chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimid-
in-6-yl]-benzyl}-acetamide using an analogous procedure as
described in Example 46: TABLE-US-00007 Example m.p. MS-ES.sup.+:
TLC HPLC Number Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R
[min] 47 N-{4-[4-(3-Chloro-4-fluoro- 245-247 522 0.53.sup.a 8.04
phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-2-(4-ethyl-
piperazin-1-yl)-acetamide 48 N-{4-[4-(3-Chloro-4-fluoro- 272-275
495 0.48.sup.b 8.19 phenylamino)-7H-pyrrolo[2,3-
d]pyrimidin-6-yl]-benzyl}-2- morpholin-4-yl-acetamide 49
N-{4-[4-(3-Chloro-4-fluoro- 229-232 495 0.48.sup.a 8.52
phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-2-
piperidin-1-yl-acetamide 50 N-{4-[4-(3-Chloro-4-fluoro- 246-249 508
0.61.sup.a 7.93 phenylamino)-7H-pyrrolo[2,3-
d]pyrimidin-6-yl]-benzyl}-2-(4- methyl-piperazin-1-yl)- acetamide
.sup.adichloromethane/methanol/conc. ammonia 40:10:1 .sup.bethyl
acetate/methanol 8:2
Example 51
N-{4-[4-(4-Benzyloxy-phendamine)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzyl}--
2-dimethylamino-acetamide
[0222]
N-{4-[4-(4-Benzyloxy-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-
-benzyl}-2-chloro-acetamide (0.2 g, 0.4 mmol) in 3 ml n-butanol and
0.215 ml (1.2 mmol) 5.6 N dimethylamine in ethanol (Fluka, Buchs,
Switzerland) is stirred and heated to 100.degree. C. for 6 h. After
addition of a second portion of dimethylamine solution (0.3 ml,
1.68 mmol) the mixture is heated for 6 more hours. The mixture is
then cooled, filtered and the solid re-suspended in 3 ml warm
dichloromethane/methanol 2:1. After cooling the title compound is
collected by filtration and purified further with flash
chromatography using a gradient of dichloromethane/methanol 100:2.5
to 10:1; m.p. 233-235; MS-ES.sup.+: (M+H).sup.+=507.
Step 51.1:
N-{4-[4-(4-Benzyloxy-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6--
yl]-benzyl}-2-chloro-acetamide
[0223] This compound is synthesized using an analogous sequence as
described for
2-chloro-N-{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-y-
l]-benzyl}-acetamide (steps 40.4 to 40.6); R.sub.f
(dichloromethane/methanol/conc. ammonia 90:10:1)=0.40; MS-ES.sup.+:
(M+H).sup.+=498.
Examples 52-53
[0224] The following Examples are synthesized from
N-{4-[4-(4-benzyloxy-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzyl-
}-2-chloro-acetamide using an analogous procedure as described in
Example 51: TABLE-US-00008 Example m.p. MS-ES.sup.+: TLC HPLC
Number Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 52
N-{4-[4-(4-Benzyloxy- 232-234 562 0.18.sup.a 8.69
phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-2-(4-
methyl-piperazin-1-yl)-acetamide 53 N-{4-[4-(4-Benzyloxy- 246-248
547 0.42.sup.b 9.31 phenylamino)-7H-pyrrolo[2,3-
d]pyrimidin-6-yl]-benzyl}-2- piperidin-1-yl-acetamide
.sup.adichloromethane/methanol/conc. ammonia 90:10:1
.sup.bdichloromethane/methanol 85:15
Example 54
N-{4-[4-((R)-1-Phenyl-ethylamino)-7H-pyrrolo[2-3-d]pyrimidin-6-yl]-benzyl}-
-3-piperidin-1-yl-propionamide
[0225] Under an atmosphere of nitrogen a mixture of 0.0865 g (0.55
mmol) 3-piperidin-1-yl-propionic acid and 0.117 ml (0.68 mmol)
N,N-diisopropylethylamine in DMF (5 ml) is treated at RT and over a
period of 5 min with a solution of 0.163 g (0.56 mmol)
O-(1,2-dihydro-2-oxo-1-pyridyl)-N,N,N',N'-tetramethyluronium-tetraflurobo-
rate (TPTU, Fluka, Buchs, Switzerland) in 2 ml DMF. After stirring
for 5 min the resulting solution is added slowly (1.5.h) at RT to
0.172 g (0.5 mmol)
[6-(4-aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-p-
henyl-ethyl)-amine (step 40.5) in 3 ml DMF. The reaction mixture is
allowed to stand over night after which the DMF is evaporated under
reduced pressure. The residue is purified by flash chromatography
using gradients of first dichloromethane/methanol 100:2.5 to 10:1
and then mixtures of dichloromethane/methanol/conc. ammonia
90:10:0.5 to 40:10:1. The title compound is obtained as yellowish
solid; m.p. 140.degree. C.; MS-ES.sup.+: (M+H).sup.+=483. As a
second product of this reaction
N-{4-[4-((R)-1-phenyt-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzyl-
}-acrylamide is obtained; m.p. 249-250.degree. C.; MS-ES.sup.+:
(M+H).sup.+=398.
Examples 55-57
[0226] The following Examples are synthesized from
[6-(4-aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyle-
thyl)-amine (step 40.5) using an analogous procedure as described
in Example 54: TABLE-US-00009 Example m.p. MS-ES.sup.+: TLC HPLC
Number Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R [min] 55
3-Diethylamino-N-{4-[4-((R)-1- 175-177 471 0.19.sup.a 8.11
phenyl-ethylamino)-7H- pyrrolo[2,3-d]pyrimidin-6-yl]-benzyl}-
propionamide 56 4-Dimethylamino-N-{4-[4-((R)- 195-203 457
0.04.sup.a 7.76 1-phenyl-ethylamino)-7H-
pyrrolo[2,3-d]pyrimidin-6-yl]- benzyl}-butyramide 57
Pyridine-2-carboxylic acid 4-[4- 221-223 449 0.51.sup.a 10.16
((R)-1-phenyl-ethylamino)-7H- pyrrolo[2,3-d]pyrimidin-6-yl]-
benzylamide .sup.adichloromethane/methanol/conc. ammonia
90:10:1
Example 58
N-{4-[4-(3-Chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-b-
enzyl}-3-diethylamino-propionamide
[0227] The title compound is synthesized from
[6-(4-aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-(3-chloro-4-fl-
uoro-phenyl)-amine using an analogous procedure as described in
Example 54. In this case activation of the carboxylic acid is done
with
(benzotriazole-1-yloxy)-tris-(dimethylamino)-phosphonium-hexafluoroborate
(BOP, Fluka, Buchs, Switzerland) and N-methylmorpholin; m.p.
229-232; HPLC t.sub.R=8.52 min; MS-ES.sup.+: (M+H).sup.+=495.
Step 58.1:
[6-(4-Aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-(3-c-
hloro-4-fluoro-phenyl)-amine
[0228] The title compound is synthesized using an analogous
procedure as described in steps 40.4 to 40.5; m.p. 350-351;
MS-ES.sup.+: (M+H).sup.30 =368.
Examples 59-61
[0229] The following Examples are synthesized from
[6-(4-aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-(3-chloro-4-fl-
uoro-phenyl)-amine (step 58.1) using an analogous procedure as
described in Example 58: TABLE-US-00010 Example m.p. MS-ES.sup.+:
TLC HPLC Number Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R
[min] 59 Pyridine-2-carboxylic acid 4-[4- 340-342 473 -- 10.62
(3-chloro-4-fluoro-phenylamino)- 7H-pyrrolo[2,3-d]pyrimidin-6-yl]-
benzylamide 60 N-{4-[4-(3-Chloro-4-fluoro- 272-273 481 0.31.sup.a
8.15 phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-4-
dimethylamino-butyramide 61 N-{4-[4-(3-Chloro-4-fluoro- 230-235 507
0.76.sup.a 8.66 phenylamino)-7H-pyrrolo[2,3-
d]pyrimidin-6-yl]-benzyl}-3- piperidin-1-yl-propionamide
.sup.adichloromethane/methanol/conc. ammonia 40:10:1
Example 62
2-Dimethylamino-N-{3-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimid-
in-6-yl]-benzyl}-acetamide
[0230] A mixture of 210 mg (0.5 mmol)
2-chloro-N-{3-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-y-
l]-benzyl}-acetamide in 3 ml dry dioxane is treated with 268 .mu.l
(1.5 mmol) of a 5.6 N dimethylamine solution in ethanol (Fluka,
Buchs, Switzerland) and then heated to 100 .degree. C. for 6 h. The
clear yellow solution is cooled and the solvent evaporated. The
residue is purified by flash chromatography using a mixture of
dichloromethane/methanol with gradually increasing concentrations
of methanol starting with 100:2.5 and ending with 100:5 and then
switching to dichloromethane/methanol/conc. ammonia starting with
100:5:0.25 and ending with 100:10:0.5. The title compound is
obtained as a colorless foam; R.sub.f
(dichloromethane/methanol/conc. ammonia 90:10:1)=0.41; MS-ES.sup.+:
(M+H).sup.+=429.
Step 62.1:
2-Chloro-N-{3-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyr-
imidin-6-yl]-benzyl}acetamide
[0231] The title compound is synthesized using an analogous
procedure as described in steps 40.1 to 40.6; m.p. 300-310
(decomposition); R.sub.f (dichloromethane/methanol/conc. ammonia
90:10:1)=0.54; MS-ES.sup.+: (M+H).sup.+=420.
Example 63
2-(4-Methyl-piperazin-1-yl)-N-{3-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2-
,3-d]pyrimidin-6-yl]-benzyl}-acetamide
[0232] The title compound is obtained as a tan resin using an
analogous procedure as described in Example 62; R.sub.f
(dichloromethanel/methanol/conc. ammonia 90:10:1)=0.20; HPLC
t.sub.R=7.77 min; MS-ES.sup.+: (M+H).sup.+=484.
Example 64
N-{3-[4-(3-Chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-b-
enzyl}-2-dimethylamino-acetamide
[0233]
2-Chloro-N-{3-[4-(3-chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]-
pyrimidin-6-yl]-benzyl}-acetamide (120 mg, 0.222 mmol) in 2 ml
dioxane and 0.145 ml (0.81 mmol) 5.6 N dimethylamine in ethanol
(Fluka, Buchs, Switzerland) is stirred and heated to 100.degree. C.
for 4.5 h. The mixture is cooled and the solvent evaporated. The
residue is shaken with THF (5 ml), dichloromethane (3 ml), methanol
(2 ml) and saturated sodium bicarbonate (2 ml). The two clear
layers are separated and the organic phase is treated with 1 g
silica gel. The solution containing the silica gel is evaporated
and the solid put on top of a flash chromatography column
containing 33 g of silica gel. The column is eluted using a mixture
of dichloromethane/methanol with gradually increasing
concentrations of methanol starting with 100:2.5 and ending with
100:5 and then switching to dichloromethane/methanol/conc. ammonia
starting with 100:5:0.25 and ending with 100:10:0.5. The title
compound is obtained as colorless crystals; m.p. 272-273.degree.
C.: MS-ES.sup.+: (M+H).sup.+=453.
Step 64.1:
2-Chloro-N-{3-[4-(3-chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-
-d]pydmidin-6-yl]-benzyl}-acetamide
[0234] The title compound is synthesized using an analogous
procedure as described in steps 40.1 to 40.6; R.sub.f
(dichloromethane/methanol/conc. ammonia 90:10:1)=0.47; HPLC
t.sub.R=9.98 min; MS-ES.sup.+: (M+H).sup.+=444.
Examples 65-66
[0235] The following Examples are synthesized from
2-chloro-N-{3-[4-(3-chloro-4-fluoro-phenylamino)-7H-pyrrolo[2,3-d]pyrimid-
in-6-yl]-benzyl}acetamide (step 64.1) using an analogous procedure
as described in Example 64: TABLE-US-00011 Example m.p.
MS-ES.sup.+: TLC.sup.a HPLC Number Name [.degree. C.] (M + H).sup.+
R.sub.f t.sub.R [min] 65 N-{3-[4-(3-Chloro-4-fluoro- 214-214 508
0.21 8.08 phenylamino)-7H-pyrrolo[2,3-
d]pyrimidin-6-yl]-benzyl}-2-(4- methyl-piperazin-1-yl)-acetamide 66
N-{3-[4-(3-Chloro-4-fluoro- 252-254 493 0.53 8.65
phenylamino)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-2-
piperidin-1-yl-acetamide .sup.aDichloromethane/methanol/conc.
ammonia 90:10:1
Examples 67-78
[0236] The following Examples are synthesized using an analogous
procedure as described in Example 1. However, a modified protocol
is applied for the preparation of the intermediates: Instead of
reducing the ethyl-ester with lithium aluminum hydride in THF (as
described in step 1.2), the 4-hydroxymethyl derivatives are
prepared by reduction with diisobutyl-aluminium hydride in a 1:1
mixture of dichloromethane and dioxane at ambient temperature
(Examples 67-72 and 76-78). For preparing the intermediates of
Examples 73-75, reduction of
4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzoic acid ethyl
ester with diisobutyl-aluminium hydride in THF at ambient
temperature yields
[4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-methanol (see
step 108.3). Substitution of the chlorine by
2-methoxy-5-aminophenol as described in step 1.1 then gives
5-[6-(4-hydroxymethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-2-met-
hoxy-phenol. TABLE-US-00012 Example m.p. MS-ES.sup.+: TLC
HPLC.sup.a Number Name [.degree. C.] (M + H).sup.+ R.sub.f t.sub.R
[min] 67 2-Methyl-5-{6-[3-(4-methyl- 256-258 429 0.14.sup.b 6.8
piperazin-1-ylmethyl)-phenyl]- 7H-pyrrolo[2,3-d]pyrimidin-4-
ylamino}-phenol 68 5-[6-(3-Dimethylaminomethyl- 258-260 374
0.21.sup.b 7.2 phenyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-ylamino]-2-methyl- phenol 69
2-Methoxy-5-{6-[3-(4-methyl- 251-252 445 0.16.sup.b 6.1
piperazin-1-ylmethyl)-phenyl]- 7H-pyrrolo[2,3-d]pyrimidin-4-
ylamino}-phenol 70 5-[6-(3-Dimethylaminomethyl- 250-251 390
0.17.sup.b 6.8 phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino]-2-
methoxy-phenol 71 5-[6-(4-Dimethylaminomethyl- 374 0.31.sup.b 7.2
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino]-2-methyl- phenol 72
2-Methyl-5-{6-[4-(4-methyl- >300 429 6.9
piperazin-1-ylmethyl)-phenyl]- 7H-pyrrolo[2,3-d]pyrimidin-4-
ylamino}-phenol 73 5-[6-(4-Dimethylaminomethyl-
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino]-2- methoxy-phenol 74
2-Methoxy-5-{6-[4-(4-methyl- 445 0.19.sup.d 6.3
piperazin-1-ylmethyl)-phenyl]- 7H-pyrrolo[2,3-d]pyrimidin-4-
ylamino}-phenol 75 2-Methoxy-5-[6-(4-morpholin-4-
ylmethyl-phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino]-phenol 76
[(R)-1-(4-Chloro-phenyl)-ethyl]- 273-274 406 0.32.sup.b 9.1
[6-(4-dimethylaminomethyl- phenyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-yl]-amine 77 [(R)-1-(4-Chloro-phenyl)-ethyl]- 232-233
461 0.31.sup.b 8.6 {6-[4-(4-methyl-piperazin-1-
ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-yl}- amine 78
[(R)-1-(4-Chloro-phenyl)-ethyl]- 448 0.16.sup.c 9.2
[6-(4-morpholin-4-ylmethyl- phenyl)-7H-pyrrolo[2,3-
d]pyrimidin-4-yl]-amine .sup.aHPLC: Column: (250 .times. 4.6 mm)
packed with reversed-phase material C18-Nucleosil (5 .mu.m mean
particle size, with silica gel covalently derivatized with
octadecylsilanes, Macherey & Nagel, Duren, Germany). Detection
by UV absorption at 215 nm. The retention times (t.sub.R) are given
in minutes. Flow rate: 1 ml/min. Gradient: 20% .fwdarw. 100% a) in
b) for 13 min + 5 min 100% a). a): Acetonitrile + 0.05% TFA; b):
water + 0.05% TFA. .sup.bDichloromethane/ethanol 4:1 + drop of
conc. ammonia .sup.cEtOAc/ethanol 9:1 .sup.dTHF/methanol 9:1 + drop
of conc. Ammonia
Example 79
(3-Chloro-phenyl)-[6-(4-dimethylaminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrim-
idin-4-yl]-amine hydrochloride
[0237] Lithium aluminum hydride (72 mg, 1.9 mmol) is suspended in
dry THF (12 ml) under a nitrogen atmosphere. Solid
4-[4-(3-chloro-phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl-
-benzamide (described in WO 97/02266, 140 mg, 0.37 mmol) is added
and the mixture heated to 60.degree. C. for 1 h. The reaction
mixture is then hydrolized at 0.degree. C. by sequential addition
of water (0.072 ml), 15% sodium hydroxide (0.072 ml) and water
(0.21 ml). The precipitate is removed by filtration and the
filtrate concentrated on a rotary evaporator. The yellow
crystalline residue is suspended in methanol, filtered, suspended
in toluene, filtered, suspended in methanol again and filtered to
give the free base of the title compound [R.sub.f
(dichloromethane/methanol 9:1 plus 1 drop of conc. ammonia)=0.36].
This is suspended in methanol (2 ml) and treated with 1 N
hydrochloric acid (0.2 ml). The suspension is stirred well and
filtered. The crystals are triturated in methanol/water 9:1 and
filtered again to give the title compound; m.p. 280-283.degree. C.;
MS-ES.sup.+: (M+H).sup.+=378.
Examples 80-81
[0238] The following Examples are synthesized from the
corresponding amides (WO 97/02266) using an analogous procedure as
described in Example 79: TABLE-US-00013 Example m.p. MS-ES.sup.+:
TLC.sup.a HPLC Number Name [.degree. C.] (M + H).sup.+ R.sub.f
t.sub.R [min] 80 (3-Chloro-phenyl)-{6-[4-(4- 227-229 433 0.35 6.74
methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine dihydrochloride 81 (3-Chloro-phenyl)-[6-(4-
278-280 420 0.49 7.25 morpholin-4-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine hydrochloride .sup.aof the
free base using dichloromethane/methanol 9:1 plus 1 drop of conc.
ammonia
Example 82
2-((2-Hydroxy-ethyl)-{4-[4-((R)-1-phenyl-ethylamino)-7H-pyrrolo[2,3-d]pyri-
midin-6-yl]-benzyl}-amino)-ethanol
[0239]
[6-(4-Aminomethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1--
phenyl-ethyl)-amine (step 40.5, 0.5 g, 1.46 mmol) is dissolved in
THF (7.5 ml) and water (0.75 ml) and cooled to -10.degree. C. A
stream of ethylene oxide is then passed through the solution for
about 40 min (amount of ethylene oxide absorbed 5 to 6 g). The
flask is sealed and the mixture stirred at 0.degree. C. for 30 min
and then at 50.degree. C. for 16 h. The clear yellow solution is
cooled and the solvents evaporated. The residue is purified by
flash chromatography on 34 g of silica gel. The column is eluted
using a mixture of dichloromethane/methanol with gradually
increasing concentrations of methanol starting with 100:1.25 and
ending with 100:2.5 and then switching to
dichloromethane/methanol/conc. ammonia starting with 100:2.5:0.125
and ending with 100:10:0.5. Fractions containing the title compound
were pooled and concentrated on a rotary evaporator. The residue is
taken up in a small amount of dichloromethane and the resulting
solid collected by filtration; m.p. 194-197.degree. C.; R.sub.f
(dichloromethane/methanol/conc. ammonia 90:10:1)=0.21; MS-ES.sup.+:
(M+H).sup.+=432.
Example 83
3-Chloro-benzyl)-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2-
,3-d]pyrimidin-4-yl}-amine
[0240]
(3-Chloro-benzylyl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]py-
rimidin-4-yl]-amine (150 mg, 0.35 mmol) is suspended in 5 ml
dioxane and treated with N-ethyl-piperazine. The mixture is heated
to 90.degree. C. for 7 h. The solvent is evaporated and the residue
is purified by flash chromatography on 34 g of silica gel. The
column is eluted using a mixture of dichloromethane/methanol with
gradually increasing concentrations of methanol starting with
100:1.25 and ending with 100:5 and then switching to
dichloromethane/methanol/conc. ammonia starting with 100:5:0.25 and
ending with 100:10:0.5. Fractions containing the title compound
were pooled and concentrated on a rotary evaporator to give the
title compound; m.p. 241-243.degree. C.; MS-ES.sup.+:
(M+H).sup.+=461.
Step 83.1:
4-[4-(3-Chloro-benzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-be-
nzoic acid ethyl ester
[0241] This compound is synthesized following an analogous
procedure as described in Example 1, step 1.1 starting from
4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzoic acid ethyl
ester (WO 97/02266) and 3-chloro-benzylamine; m.p. 305-306.degree.
C.; MS-ES.sup.+: (M+H).sup.+=407.
Step 83.2:
{4-[4-(3Chloro-benzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-ph-
enyl}methanol
[0242] 2.236 g (0.059 mol) lithium aluminum hydride are suspended
in 600 ml dry THF at RT.
4-[4-(3-Chloro-benzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzoic
acid ethyl ester (4.8 g, 0.0118 mol) is added in portions over 5
min and the resulting mixture is heated to 60.degree. C. for 1 h.
The mixture is cooled in an ice bath to about 10.degree. C. and
treated sequentially with THF/water 1:1 (2.24 ml), 15% sodium
hydroxide solution (4.48 ml) and water (6.72 ml). The solid
aluminum complex is removed by filtration (Hyflo Super Cel.RTM.;
Fluka, Buchs, Switzerland) and washed thoroughly with THF. The
filtrate is concentrated to about 50 ml and the resulting
suspension treated with water/ethanol 9:1 (50 ml). After stirring
for 10 min the crystals were collected by filtration and dried
under reduced pressure to give the title compound; m.p.
296-298.degree. C.; MS-ES.sup.+: (M+H).sup.+=365.
Step 83.3:
(3-Chloro-benzyl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]p-
yrimidin-4-yl]-amine
[0243] A solution of 0.79 ml (10 mmol) thionylchloride in 5.5 ml of
toluene is cooled to -10.degree. C. Solid
{4-[4-(3-chloro-benzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenyl}-met-
hanol is added and the suspension stirred at 0.degree. C. for 2 h
and then at RT for 17 h. The solid is filtered off, washed with
toluene and suspended in water (3 ml). The mixture is treated with
saturated sodium bicarbonate solution (3 ml) and stirred for 10
min. The crystals are collected by filtration washed with water, a
small amount of ethanol and ether and dried to give the title
compound; m.p. decomposition .about.300.degree. C.; R.sub.f
(dichloromethane/methanol/conc. ammonia 90:10:1)=0.61; MS-ES.sup.+:
(M+H).sup.+=383.
Examples 84-107i
[0244] The following Examples are synthesized using an analogous
procedure as described in Example 83: TABLE-US-00014 Example m.p.
MS-ES.sup.+: TLC HPLC Number Name [.degree. C.] (M + H).sup.+
R.sub.f t.sub.R [min] 84 (3-Chloro-benzyl)-[6-(4- 219-222 393 --
7.46 dimethylaminomethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 85 (3-Chloro-benzyl)-[6-(4- 234-235 432 0.44.sup.a 795
piperidin-1-ylmethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 86 (3-Chloro-benzyl)-[6-(4- 253-254.5 434 -- 7.55
morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 87 (3-Chloro-benzyl)-[6-(4- 231-233 420 0.35.sup.a 7.86
diethylaminomethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]- amine
88 (3-Chloro-benzyl)-[6-(4- 222-225 418 0.32.sup.a 777
pyrrolidin-1-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 89 (3-Chloro-benzyl)-{6-[4-(4- 235-237 447 0.34.sup.a 6.99
methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 90 (2-Chloro-benzyl)-[6-(4- 256-258 392
0.30.sup.a 7.65 dimethylaminomethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 91
(2-Chloro-benzyl)-{6-[4-(4-ethyl- 255-256 461 0.23.sup.a 7.37
piperazin-1-ylmethyl)-phenyl]- 7H-pyrrolo[2,3-d]pyrimidin-4-yl}-
amine 92 (2-Chloro-benzyl)-[6-(4- 262-264 432 0.54.sup.a 7.77
piperidin-1-ylmethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 93 (2-Chloro-benzyl)-[6-(4- 276-279 434 0.42 7.39
morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 94 (2-Chloro-benzyl)-{6-[4-(4- 267-269 447 0.37.sup.a 6.80
methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 95 (2-Chloro-benzyl)-[6-(4- 264-265 418
0.33.sup.a 7.59 pyrrolidin-1-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 96 (2-Chloro-benzyl)-[6-(4-
257-258 420 0.42.sup.a 7.69 diethylaminomethyl-phenyl)-7H-
pyrrolo[2,3-d]pyrimidin-4-yl]- amine 97
(2,5-Dichloro-benzyl)-{6-[4-(4- 249-251 495 0.30.sup.a 7.44
ethyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 98 (2,5-Dichloro-benzyl)-[6-(4- 254-257 426
0.30.sup.a 7.91 dimethylaminomethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 99
(2,5-Dichloro-benzyl)-[6-(4- 272-274 468 0.42.sup.b 7.97
morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 100 (2,5-Dichloro-benzyl)-[6-(4- 258-260 466 -- 8.44
piperidin-1-ylmethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 101 (2,5-Dichloro-benzyl)-[6-(4- 255-257 454 0.50.sup.c 8.26
diethylaminomethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]- amine
102 (2,5-Dichloro-benzyl)-{6-[4-(4- 244-246 481 0.37.sup.c 7.43
methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 103 (2,5-Dichloro-benzyl)-[6-(4- 266-268
452 0.48.sup.a 8.20 pyrrolidin-1-ylmethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 104
[6-(4-Dimethylaminomethyl- 227-229 388 0.40.sup.d 6.91
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-(3-methoxy- benzyl)-amine
105 [6-(4-Diethylaminomethyl- 230-232 416 0.57.sup.d 7.36
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-(3-methoxy- benzyl)-amine
106 (3-Methoxy-benzyl)-[6-(4- 220-222 414 0.50.sup.d 7.29
pyrrolidin-1-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 107 (3-Methoxy-benzyl)-[6-(4- 227-229 428 0.30.sup.e 7.48
piperidin-1-ylmethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 107a (3-Methoxy-benzyl)-[6-(4- 263-265 430 0.42.sup.f 7.02
morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 107b (3-Methoxy-benzyl)-{6-[4-(4- 225-227 443 0.12.sup.f 6.43
methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 107c {6-[4-(4-Ethyl-piperazin-1- 231-233
457 0.45.sup.f 6.66 ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-yl}-(3- methoxy-benzyl)-amine 107d
(3-Methyl-benzyl)-[6-(4- 246-248 412 0.46.sup.f 7.88
piperidin-1-ylmethyl-phenyl)-7H- pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 107e (3-Methyl-benzyl)-[6-(4- 259-261 414 0.37.sup.f 7.74
morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 107f [6-(4-Dimethylaminomethyl- 230-232 372 0.58.sup.d 7.23
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-(3-methyl- benzyl)-amine
107g [6-(4-Diethylaminomethyl- 241-243 400 0.6.sup.d 7.71
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]-(3-methyl- benzyl)-amine
107h (3-Methyl-benzyl)-[6-(4- 241-243 398 0.5.sup.d 7.63
pyrrolidin-1-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 107i (3-Methyl-benzyl)-{6-[4-(4- 244-246 427 0.5.sup.d 6.87
methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 107j {6-[4-(4-Ethyl-piperazin-1- 250-252
441 0.4.sup.d 6.9 ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-yl}-(3- methyl-benzyl)-amine
.sup.aDichloromethane/methanol/conc. ammonia 90:10:1
.sup.bDichloromethane/ethanol/conc. ammonia 92:8:1
.sup.cDichloromethane/ethanol/conc. ammonia 93:7:1
.sup.dDichloromethane/ethanol/conc. ammonia 90:10:1
.sup.eDichloromethane/methanol 80:20 .sup.fDichloromethane/methanol
80:20
Example 108
Benzo[1,3]dioxol-5-yl-{6-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-7H-pyr-
rolo[2,3-d]pyrimidin-4-yl}-amine
[0245] A mixture of 200 mg (0.53 mmol)
benzo[1,3]dioxol-5-yl-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimid-
in-4-yl]-amine, 0.59 ml (5.3 mmol) 1-methyl-piperazine and a trace
of NaI in 15 ml ethanol is stirred for 4 h at 65.degree. C. and 2 h
at 80.degree. C. under N.sub.2-atmosphere. The orange solution is
concentrated under vacuum and the residue resolved with ethyl
acetate and NaHCO.sub.3-solution. The aqueous layer is separated
off and extracted twice with ethyl acetate. The organic phases are
washed with water and brine, dried (MgSO.sub.4) and partially
concentrated. Then the crystallized title compound can be filtered
off; MS-ES.sup.+: (M+H).sup.+=443; HPLC (conditions see Examples
67-78) t.sub.R=7.1 min.
Step 108.1:
[4-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-methanol
[0246] To a suspension of 30.0 g (100 mmol)
4-(4-chtoro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzoic acid ethyl
ester (WO 97/02266) in 450 ml dry THF at 10.degree. C. under
N.sub.2-atmosphere, 500 ml -diisobutyl-aluminium hydride (1 M in
THF) were added dropwise. The resulting clear solution is stirred
for 1 h and then diluted with 2.1 l of dry THF. Then 98 ml of ethyl
acetate are added, followed after 15 min by 45 ml of water and
after 1 h by 22.5 ml of 4 N sodium hydroxide. After 1 h stirring,
200 g of Na.sub.2SO.sub.4 are added and stirring is continued for
another hour. The mixture is filtered through Celite (Fluka, Buchs,
Switzerland), the residue washed with THF and discarded.
Concentration of the filtrate to a volume of .apprxeq.0.1 l,
addition of 0.3 l of dichloromethane and filtration yields the
title compound; Analysis for C.sub.13H.sub.10ClN.sub.3O: calc. C,
60.13%; H, 3.88%; N, 16.18%; Cl, 13.65%; found C, 60.23%; H, 4.03%;
N, 16.51%; Cl, 13.28%.
Step 108.2:
{4-[4-(Benzo[1,3]dioxol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-pheny-
l}-methanol
[0247] A mixture of 1.5 g (5.8 mmol) of
[4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-methanol and
1.58 g (11.5 mmol) 3,4-methylendioxy-aniline in 30 ml n-butanol is
stirred for 16 h at 115.degree. C. under N.sub.2atmosphere. After
cooling to ambient temperature, the title compound can be filtered
off and washed with n-butanol; MS-ES.sup.+: (M+H).sup.+=361; HPLC
(conditions see Examples 67-78) t.sub.R=8.7 min.
Step 108.3:
Benzo[1,3]dioxol-5-yl-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimid-
in-4-yl]-amine
[0248] To a suspension of 1.83 g of
{4-[4-(benzo[1,3]dioxol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-pheny-
l}-methanol in 56 ml of dioxane/acetonitrile 1:1 under
N.sub.2-atmosphere, 3.1 ml of thionylchloride are added. After 16 h
stirring, the suspension is diluted with ethyl acetate and
NaHCO.sub.3-solution. The aqueous layer is separated off and
extracted twice with ethyl acetate. The organic phases are washed
with water and brine, dried (MgSO.sub.4) and concentrated to yield
the title compound; MS-ES.sup.+: (M+H).sup.+=379; HPLC (conditions
see Examples 67-78) t.sub.R =11.4 min.
Examples 108a-114
[0249] The following Examples are synthesized using an analogous
procedure as described in Example 108: TABLE-US-00015 Example m.p.
MS-ES.sup.+: TLC HPLC.sup.a Number Name [.degree. C.] (M + H).sup.+
R.sub.f t.sub.R [min] 108a Benzo[1,3]dioxol-5-yl-{6-[4-(4- 457
0.32.sup.c 7.3 ethyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 109 Benzo[1,3]dioxol-5-yl-[6-(4- 388
0.08.sup.b 7.6 dimethylaminomethyl-phenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]- amine 110
Benzo[1,3]dioxol-5-yl-[6-(4- 430 0.16.sup.b 7.7
morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 111 (6-Methoxy-pyridin-3-yl)-[6-(4- 263-264 417 0.78.sup.c
7.2 morpholin-4-ylmethyl-phenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-yl]-
amine 112 (6-Methoxy-pyridin-3-yl)-{6-[4- 241-242 430 0.07.sup.b
6.9 (4-methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 113 (6-Methoxy-pyridin-3-yl)-{6-[4- 375
0.49.sup.c 7.0 (dimethylamino-methyl)-phenyl]-
7H-pyrrolo[2,3-d]pyrimidin-4-yl}- amine 114
(6-Methoxy-pyridin-3-yl)-{6-[4- 444 0.41.sup.c 6.8
(4-ethyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine .sup.aHPLC: conditions see Examples 67-78
.sup.bDichloromethane/methanol/conc. ammonia 90:10:1
.sup.cTHF/methanol/conc. ammonia 90:10:1
Example 115
5-[6-(4-Morpholin-4-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino]-
-1H-pyridin-2-one
[0250] To 84 mg (0.20 mmol) of
(6-methoxy-pyridin-3-yl)-[6-(4-morpholin-4-ylmethyl-phenyl)-7H-pyrrolo[2,-
3-d]pyrimidin-4-yl]-amine and 10 ml chloroform in an ampoule under
N.sub.2-atmosphere, 0.1 ml (0.73 mmol) Me.sub.3Sil is added. After
stirring for 6 h at 70.degree. C., diluted NaHCO.sub.3 solution and
EtOAc is added to the suspension at RT. Stirring, filtration and
washing with water yields the title compound; TLC
(THF/methanol/conc. ammonia 90:10:1) R.sub.f=0.23; MS-ES.sup.+:
(M+H).sup.+=403; HPLC (conditions see Examples 67-78) t.sub.R=4.7
min.
Examples 116-118
[0251] The following Examples are synthesized using an analogous
procedure as described in Example 115 (eventually after
purification with chromatography on SiO.sub.2 or reversed phase
medium pressure liquid chromatography: Nucleosil C.sub.18,
CH.sub.3CN/H.sub.2O+TFA): TABLE-US-00016 Example MS-ES.sup.+: TLC
HPLC.sup.a Number Name (M + H).sup.+ R.sub.f t.sub.R [min] 116
5-[6-(4-Dimethylaminomethyl- 361 0.09.sup.d 9.2.sup.b
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino]-1H- pyridin-2-one
117 5-{6-[4-(4-Methyl-piperazin-1- 416 9.0.sup.c
ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-
ylamino}-1H-pyridin-2-one 118 5-{6-[4-(4-Ethyl-piperazin-1- 430
9.1.sup.c ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-
ylamino}-1H-pyridin-2-one .sup.aHPLC: solvent system: a):
Acetonitrile + 0.05% TFA; b): water + 0.05% TFA. .sup.bGrad: 20%
.fwdarw. 100% a) in b) for 13 min + 5 min 100% a). .sup.cGrad: 5%
.fwdarw. 40% a) in b) for 9 min + 7 min 40% a).
.sup.dTHF/methanol/conc. ammonia 90:10:1
Example 119
(6-Methoxy-pyridin-3-ylmethyl)-{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl-
]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amine
[0252]
(6-Methoxy-pyridin-3-ylmethyl)-[6-(4-chloromethyl-phenyl)-7H-pyrro-
lo[2,3-d]pyrimidin-4-yl]-amine (400 mg, 1.05 mMol), 1.34 ml
N-ethyl-piperazine and a trace of NaI is stirred for 2.5 h in 30 ml
boiling ethanol. The solvent is evaporated and the residue is
re-dissolved in EtOAc and diluted NaHCO.sub.3-solution. The
separated aqueous layer is re-extracted with EtOAc and the organic
phases are washed with water and brine, dried (Na.sub.2SO.sub.4)
and partially concentrated in vacuuo. The title compound
crystallizes and can be filtered off; MS-ES.sup.+: (M+H).sup.+=458;
elemental analysis for C, H, and N, within 0.5% of calculated
value.
[0253] Step 119.1:
4-[4-(6-Methoxy-pyridin-3-ylmethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-
-benzoic acid ethyl ester
[0254] A mixture of 5.0 g (16.6 mMol)
4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzoic acid ethyl
ester (WO 97/02266) and 2.52 g (18 mMol) of
6-methoxy-pyridin-3-ylmethylamine (CAS: 262295-96-5; prepared from
6-methoxy-nicotin-nitrile by hydrogenation in the presence of
Raney-Nickel in methanol containing NH.sub.3) in 3.5 ml (25 mMol)
of Et.sub.3N and 100 ml n-butanol is heated for 8 h to 140.degree.
C. Then additional 0.69 g of 6-methoxy-pyridin-3-ylmethylamine and
1.2 ml of Et.sub.3N are added. Heating is continued for 6 h and the
hot suspension filtrated and the residue washed with n-butanol and
hexane to give the title compound; m.p. 305.degree. C.; elemental
analysis for C, H, and N, within 0.5% of calculated value.
Step 119.2:
{4-[4-(6-Methoxy-pyridin-3-ylmethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-phenyl}-methanol
[0255] 5.0 g (12 mMol) of
4-[4-(6-methoxy-pyridin-3-ylmethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-
-benzoic acid ethyl ester in 200 ml of THF is cooled to -10.degree.
C. Then 80 ml of a 1 N solution of di-isobutyl-aluminium hydride in
THF are added dropwise. After stirring for 3 h at RT, 200 ml of THF
and 100 ml of EtOAc are added, followed by 10 ml of a 10%-solution
of NH.sub.4Cl in water. After 30 min vigorous stirring, 20 g of
Na.sub.2SO.sub.4 are added, then the mixture is filtered through
Celite. Concentration of the filtrate, stirring in methanol and
filtration gives the title compound; MS-ES.sup.+:
(M+H).sup.+=362.
Step 119.3:
(6-Methoxy-pyridin-3-ylmethyl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3--
d]pyrimidin-4-yl]-amine
[0256] A suspension of 3.28 g (9.1 mMol) of
{4-[4-(6-methoxy-pyridin-3-ylmethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-phenyl}-methanol in 40 ml of acetonitrile, 40 ml of dioxane and 4
ml of SOCl.sub.2 is stirred for 1 h at RT. The mixture is dissolved
in EtOAc and NaHCO.sub.3-solution, the aqueous layer separated off
and extracted with EtOAc. The organic layers are washed with
NaHCO.sub.3-solution, water and brine, dried (Na.sub.2SO.sub.4) and
partially concentrated. The crystallized title compound can be
filtered off, elemental analysis for C, H, and N, within 0.4%; of
calculated value.
Examles 120-125
[0257] The following Examples are synthesized analogously:
TABLE-US-00017 Example m.p. MS-ES.sup.+: HPLC.sup.a Elem. Number
Name [.degree. C.] (M + H).sup.+ t.sub.R [min] anal..sup.b 120
(6-Methoxy-pyridin-3-ylmethyl)- 431 7.2 CHN
{6-[4-(morpholin-4-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 121 (6-Methoxy-pyridin-3-ylmethyl)- 389 7.1
CHN {6-[4-(dimethylamino-methyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 122 (2-Methoxy-pyridin-4-ylmethyl)- 210-212
458 6.6 {6-[4-(4-ethyl-piperazin-1- ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-yl}-amine.sup.c 123
(2-Methoxy-pyridin-4-ylmethyl)- 431 7.0
{6-[4-(morpholin-4-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine.sup.c 124 (2-Methoxy-pyridin-4-ylmethyl)-
210-211 389 6.8 CHN {6-[4-(dimethylamino-methyl)-
phenyl]-7H-pyrrolo[2,3- d]pyrimidin-4-yl}-amine.sup.c 125
(2-Methoxy-pyridin-4-ylmethyl)- 211-212 444 6.3 CHN
{6-[4-(4-methyl-piperazin-1- ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-yl}- amine.sup.c .sup.aHPLC: solvent
system: a): Acetonitrile + 0.05% TFA; b): water + 0.05% TFA: Grad:
20% .fwdarw. 100% a) in b) for 13 min + 5 min 100% a).
.sup.bexperimental value within 0.4% of calculated one
.sup.c2-Methoxy-pyridin-4-ylmethylamine used [preparation see J.
Med. Chem. 36 (1993), 2362]
Examples 126-132
[0258] Cleavage of the methylether of the above compounds
analogously to Example 115 gives: TABLE-US-00018 Example m.p.
MS-ES.sup.+: HPLC.sup.a Elem. Number Name [.degree. C.] (M +
H).sup.+ t.sub.R [min] anal..sup.d 126
5-({6-[4-(4-Ethyl-piperazin-1- 444 9.4.sup.b ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4- ylamino}-methyl)-1H-pyridin-2- one 127
5-({6-[(4-(Dimethylamino- 375 9.6.sup.b CHN
methyl)-phenyl]-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino}-methyl)-
1H-pyridin-2-one 128 5-({6-[4-(4-Morpholin-ylmethyl)- 417 9.7.sup.b
CHN phenyl]-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino}-methyl)-
1H-pyridin-2-one 129 4-({6-[4-(4-Ethyl-piperazin-1- 291-292 444
9.4.sup.b ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-
ylamino}-methyl)-1H-pyridin-2- one 130
4-({6-[4-(4-Morpholin-ylmethyl)- 417 5.7.sup.c CHN
phenyl]-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino}-methyl)-
1H-pyridin-2-one 131 4-({6-[(4-(Dimethylamino- 330-332 375
5.6.sup.c CHN methyl)-phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-ylamino}-methyl)- 1H-pyridin-2-one 132
4-({6-[4-(4-Methyl-piperazin-1- 5.0.sup.c CHN ylmethyl)-phenyl]-7H-
pyrrolo[2,3-d]pyrimidin-4- ylamino}-methyl)-1H-pyridin-2- one
.sup.aHPLC: solvent system: a): Acetonitrile + 0.05% TFA; b): water
+ 0.05% TFA. .sup.bGrad: 5% .fwdarw. 40% a) in b) for 9 min + 7 min
40% a). .sup.cGrad: 20% .fwdarw. 100% a) in b) for 13 min + 5 min
100% a). .sup.dexperimental value within 0.4% of calculated one
Example 133
(2-Methoxy-pyridin-4-yl)-[6-(4-morpholin-4-ylmethyl-phenyl)-7H-pyrrolo[2,3-
-d]pyrimidin-4-yl]-amine
[0259] 330 mg (0.90 mMol)
(2-Methoxy-pyridin-4-yl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyri-
midin-4-yl]-amine, 0.81 ml morpholine and a trace of NaI is stirred
for 2 h in 20 ml boiling ethanol. A clear solution is formed from
which upon cooling to RT the title compound crystallizes out and
can be filtered off; TLC (CH.sub.2Cl.sub.2/methanol 9:1)
R.sub.f=0.33; MS-ES.sup.+: (M+H).sup.+=417.
Step 133.1:
{4-[4-(2-Methoxy-pyridin-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phen-
yl}-methanol
[0260] To 4.16 g (16 mMol) of
[4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-phenyl]-methanol (see
Step 108.3) and 1.99 g (16 mMol) of 2-methoxy-pyridin-4-ylamine
[see Rec. Trav. Chim. (1955) 74, 1160; prepared from
2-methoxy-4-nitro-pyridine-1-oxide by hydrogenation in the presence
of Raney-Nickel in methanol/THF] in 90 ml degassed DMF under
N.sub.2-atmosphere, 996 mg of R(+)-BINAP
[R(+)-2,2'-bis-(diphenylphosphino)-1,1'-binaphthalin); 1.6 mMol],
414 mg Pd.sub.2(dba).sub.3.CHCl.sub.3
[tris(dibenzylideneacetone)dipalladium (0) chloroform complex; 0.40
mMol] and 3.08 g (32 mMol) of sodium-tert-butylate are subsequently
added. The red solution is stirred at 70.degree. C. over night and
then poured into a mixture of 0.5 l of EtOAc and 1 l buffer (7.8 g
of NaH.sub.2PO.sub.4.2H.sub.2O, 5 g of Na.sub.2HPO.sub.4.2H.sub.2O
in 1 l H.sub.2O). After stirring for 1 h, the title compound is
filtered off and washed with water and EtOAc; HPLC (conditions see
Examples 67-78) t.sub.R=8.2 min; MS-ES.sup.+: (M+H).sup.+=348.
Step 133.2:
(2-Methoxy-pyridin-4-yl)-[6-(4-chloromethyl-phenyl)-7H-pyrrolo[2,3-d]pyri-
midin-4-yl]-amine
[0261] At 0.degree. C., a suspension of 1.23 g (3.5 mMol) of
{4-[4-(2-methoxy-pyridin-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-phen-
yl}-methanol in 18 ml of acetonitrile, 18 ml of dioxane and 1.5 ml
of SOCl.sub.2 is prepared at 0.degree. C. and then stirred for 4.5
h at RT. The mixture is diluted with 0.2 l of EtOAc and 0.1 l of
saturated NaHCO.sub.3-solution, stirred and the title compound off;
MS-ES.sup.+: (M+H).sup.+=366. More product can be obtained by
extraction of the filtrate.
Examples 134-140
[0262] The following Examples are synthesized by preparing the
corresponding methoxy pyridines analogously to Example 133 followed
by de-methylation to the corresponding pynidones as described in
Example 115: TABLE-US-00019 Example MS-ES.sup.+: HPLC.sup.a Elem.
TLC Number Name (M + H).sup.+ t.sub.R [min] anal..sup.b R.sub.f 134
4-[6-(4-Morpholin-4-ylmethyl- 403 7.3 0.24.sup.c
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino]-1H- pyridin-2-one
135 (2-Methoxy-pyridin-4-yl)-{6-[4- 430 7.2 0.35.sup.c
(4-methyl-piperazin-1-ylmethyl)- phenyl]-7H-pyrrolo[2,3-
d]pyrimidin-4-yl}-amine 136 4-{6-[4-(4-Methyl-piperazin-1- 416 7.0
0.08.sup.c ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-
ylamino}-1H-pyridin-2-one 137 (2-Methoxy-pyridin-4-yl)-{6-[4- 444
7.7 0.48.sup.d (4-ethyl-piperazin-1-ylmethyl)-
phenyl]-7H-pyrrolo[2,3- d]pyrimidin-4-yl}-amine 138
4-{6-[4-(4-Ethyl-piperazin-1- 430 7.2 0.10.sup.c
ylmethyl)-phenyl]-7H- pyrrolo[2,3-d]pyrimidin-4-
ylamino}-1H-pyridin-2-one 139 [6-(4-Dimethylaminomethyl- 375 7.2
CHN 0.47.sup.d phenyl)-7H-pyrrolo[2,3-d]pyrimidin-
4-yl]-(2-methoxy-pyridin-4-yl)-amine 140
4-[6-(4-Dimethylaminomethyl- 361 7.2 0.08.sup.c
phenyl)-7H-pyrrolo[2,3- d]pyrimidin-4-ylamino]-1H-pyridin-2- one
.sup.aHPLC: solvent system: a): Acetonitrile + 0.05% TFA; b): water
+ 0.05% TFA. Grad: 20% .fwdarw. 100% a) in b) for 13 min + 5 min
100% a). .sup.bexperimental value within 0.4% of calculated one
.sup.cCH.sub.2Cl.sub.2/MeOH/NH.sub.3.sup.conc. 80:20:1
.sup.dTHF/MeOH/NH.sub.3.sup.conc. 90:10:0.3
Example 141
6-[4-(4-Ethyl-piperazin-1-ylmethyl)-phenyl]-4-(4-fluoro-2-methyl-1H-indol--
5-yloxy)-7H-pyrrolo[2,3-d]pyrimidine
[0263] 1.56 ml of diisobutyl-aluminium hydride (1 M in THF) are
added to a solution of 130 mg (0.26 mMol) of
(4-ethyl-piperazin-1-yl)-{4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-py-
rrolo[2,3-d]pyrimidin-6-yl]-phenyl}methanone in 13 ml of THF at
-15.degree. C. under a N.sub.2-atmosphere. After 3 h, 4 ml of EtOAc
are added to the solution, followed by 0.2 ml of a saturated
solution of NH.sub.4Cl in water. After adding solid
Na.sub.2SO.sub.4, the reaction mixture is filtered through Celite.
The filtrate is concentrated together with 3 g of SiO.sub.2. The
resulting powder is put on top of a chromatography column
(SiO.sub.2) and then eluted with EtOAc/methanol 4:1 and finally
EtOAc/methanol/NEt.sub.3 80:20:1, yielding the title compound; HPLC
(conditions see Examples 67-78) t.sub.R=10.5 min; MS-ES.sup.+:
(M+H).sup.+=485.
Step 141.1:
4-[4-Chloro-1-(4-methox-benzyl)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzoic
acid ethyl ester
[0264] A suspension of 3.0 g (10 mMol) of
4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-benzoic acid ethyl
ester (WO 97/02266), 2.4 g (17 mMol) of K.sub.2CO.sub.3, 0.32 g (1
mMol) of tetrabutyl-ammoniumbromide and 2.0 ml (15 mMol) of
4-methoxy-benzylchloride in 25 ml of 2-butanone is stirred for 18 h
at 80.degree. C. Then the suspension is filtered, the residue
washed with 2-butanone and discarded. The filtrate is diluted with
EtOAc and water, the aqueous layer separated off and extracted
twice with EtOAc. The organic layers are washed with water and
brine, dried (Na.sub.2SO.sub.4) and concentrated after adding 13 g
of SiO.sub.2. The resulting powder is put on top of a
chromatography column (SiO.sub.2) and then eluted with hexane/EtOAc
2:1.
4-[4-Chloro-7-(4-methoxy-benzyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzoic
acid ethyl ester [TLC (hexane/EtOAc 2:1) R.sub.f=0.40; MS-ES.sup.+:
(M+H).sup.+=422] is eluated first, followed by the title compound;
TLC (hexane/EtOAc 2:1) R.sub.f=0.23; MS-ES.sup.+:
(M+H).sup.+=422.
Step 141.2:
4-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-1-(4-methoxy-benzyl)-1H-pyrrolo-
[2,3-d]pyrimidin-6-yl]-benzoic acid ethyl ester
[0265] A mixture of 3.96 g (9.4 mMol) of
4-[4-chloro-1-(4-methoxy-benzyl)-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-benzoic
acid ethyl ester, 2.14 g (13 mMol) of
4-fluoro-5-hydroxy-2-methyl-1H-indole (preparation see WO 00/47212;
Ex. 237) and 2.44 (17.7 mMol) of K.sub.2CO.sub.3 in 90 ml of DMF is
heated for 9 h at 95.degree. C. The reaction mixture is
concentrated in vacuuo, the residue dissolved in EtOAc and water,
the aqueous layer separated off and extracted twice with EtOAc. The
organic layers are washed with water and brine, dried
(Na.sub.2SO.sub.4) and concentrated. Column chromatography
(SiO.sub.2, EtOAc/hexane 1:1) gives the title compound; TLC
(EtOAc/hexane 1:1) R.sub.f=0.24; MS-ES.sup.+: (M+H).sup.+=551.
Step 141.3:
4-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-benzoic acid ethyl ester
[0266] Hydrogenation of 0.50 g (0.91 mMol) of
4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-1-(4-methoxy-benzyl)-1H-pyrrolo-
[2,3-d]pyrimidin-6-yl]-benzoic acid ethyl ester in 150 ml of THF
and 15 ml of 1,3-dimethyl-2-imidazolidinone in the presence of 0.2
g of Pd/C (10%; "Engelhard 5125"), filtration and concentration
gives the crude product. Stirrng in THF/water, filtration and
washing with water gives the title compound; MS-ES.sup.+:
(M+H).sup.+=431; elemental analysis for C, H, N, and ,F within
0.4%; of calculated value.
Step 141.4:
4-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-benzoic acid lithium salt
[0267] A suspension of 2.87 g (6.7 mMol) of
4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-benzoic acid ethyl ester and 520 mg (12 mMol) LiOH.H.sub.2O in
240 ml of dioxane and 5 ml of water is stirred for 24 h at
120.degree. C. The solid is dissolved first, then a new precipitate
is formed. Filtration at RT and washing with dioxane and
diethylether gives the title compound; HPLC (conditions see
Examples 67-78) t.sub.R=13.5 min; MS-ES.sup.+: (M+H).sup.+=403.
Step 141.5:
(4-Ethyl-piperazin-1-yl)-{4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-py-
rrolo[2,3-d]pyrimidin-6-yl]-phenyl}-methanone
[0268] To 340 mg (0.83 mMol)
4-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-7H-pyrrolo[2,3-d]pyrimidin-6-yl-
]-benzoic acid lithium salt in 5 ml of DMF under
N.sub.2-atmosphere, 0.38 ml (3 mMol) of N-ethylpiperazine and 0.31
ml (95%; 2 mMol) of diethyl-cyanphosphonate are added at 0.degree.
C. After 60 min, the suspension is diluted with EtOAc and washed
with saturated NaHCO.sub.3-solution, water and brine. The aqueous
layers are reextracted twice with EtOAc, the organic layers dried
(Na.sub.2SO.sub.4) and concentrated after adding SiO.sub.2. The
resulting powder is put on top of a chromatography column
(SiO.sub.2) and the title compound eluted with
EtOAc/methanol/NH.sub.3.sup.conc. 80:20:1; HPLC (conditions see
Examples 67-78) t.sub.R=10.4 min; MS-ES.sup.+: (M+H).sup.+=499.
Examples 142-144
[0269] The following Examples are synthesized analogously to
Example 141: TABLE-US-00020 Example MS-ES.sup.+: HPLC.sup.a Elem.
m.p. TLC Number Name (M + H).sup.+ t.sub.R [min] anal..sup.b
[.degree. C.] R.sub.f 142 6-[4-(4-Methyl-piperazin-1- 471 12.8 CHNF
ylmethyl)-phenyl]-4-(4-fluoro-2- methyl-1H-indol-5-yloxy)-7H-
pyrrolo[2,3-d]pyrimidine 143 4-(4-Fluoro-2-methyl-1H-indol-5- 458
10.7 280-282 0.19.sup.c yloxy)-6-(4-morpholin-4-
ylmethyl-phenyl)-7H-pyrrolo[2,3- d]pyrimidine 144
{4-[4-(4-Fluoro-2-methyl-1H- 416 10.7 0.21.sup.d
indol-5-yloxy)-7H-pyrrolo[2,3- d]pyrimidin-6-yl]-benzyl}-
dimethyl-amine .sup.aHPLC: solvent system: a): Acetonitrile + 0.05%
TFA; b): water + 0.05% TFA. Grad: 20% .fwdarw. 100% a) in b) for 13
min + 5 min 100% a). .sup.bexperimental value within 0.4% of
calculated one .sup.cEtOAc/MeOH 19:1 .sup.dEtOAc/MeOH/NEt.sub.3
80:20:1
Example 145
Dry-filled Capsules
[0270] 5000 capsules, each comprising as active ingredient 0.25 g
of one of the compounds of formula I mentioned in the preceding
Examples, are prepared as follows: TABLE-US-00021 Composition
active ingredient 1250 g talcum 180 g wheat starch 120 g magnesium
stearate 80 g lactose 20 g
[0271] Preparation process: The mentioned substances are pulverised
and forced through a sieve of 0.6 mm mesh size. 0.33 g portions of
the mixture are introduced into gelatin capsules using a
capsule-filling machine.
Example 146
Soft Capsules
[0272] 5000 soft gelatin capsules, each comprising as active
ingredient 0.05 g of one of the compounds of formula I mentioned in
the preceding Examples, are prepared as follows: TABLE-US-00022
Composition active ingredient 250 g PEG 400 1 litre Tween 80 1
litre
[0273] Preparation process: The active ingredient is pulverised and
suspended in PEG 400 (polyethylene glycol having an M.sub.r of from
approx. 380 to approx. 420, Fluka, Switzerland) and Tween.RTM.80
(polyoxyethylene sorbitan monolaurate, Atlas Chem. Ind. Inc., USA,
supplied by Fluka, Switzerland) and ground in a wet pulveriser to a
particle size of approx. from 1 to 3 .mu.m. 0.43 g portions of the
mixture are then introduced into soft gelatin capsules using a
capsule-filling machine.
Example 147
Inhibition of the Tyrosine Kinase Activity of EGF-R (HER-1), ErbB-2
(HER-2) and VEGF Receptor (KDR)
[0274] The inhibition tests are carried out as described above. The
IC.sub.50 values for some of the compounds of formula I are given
below: TABLE-US-00023 Compound from HER-1 HER-2 KDR Example No.
IC.sub.50 [.mu.M] IC.sub.50 [.mu.M] IC.sub.50 [.mu.M] 3 0.0031
0.008 0.0107 4 0.0031 0.0072 0.0093 5 0.0031 0.0067 0.006 6 0.007
0.005 0.0127 7 0.004 0.011 0.058 8a 0.0024 0.0094 0.017 10 0.004
0.009 0.0293 11 0.0043 0.005 0.0497 12 0.0047 0.005 0.1387 13 0.006
0.005 0.088 14 0.0063 0.0085 0.0927 15 0.005 0.0065 0.0493 16a
0.0012 0.016 0.061 18 0.0165 0.0315 0.0245 43 0.005 0.0115 0.0515
48 0.0057 0.0075 0.058 52 0.0157 0.014 0.125 86 0.0055 0.016 0.105
94 0.0018 0.016 0.042 107f 0.0025 0.045 0.019 116 0.039 0.0155
0.0155
* * * * *